<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Toxins (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Toxins (Basel)</journal-id><journal-id journal-id-type="publisher-id">toxins</journal-id><journal-title-group><journal-title>Toxins</journal-title></journal-title-group><issn pub-type="epub">2072-6651</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39998108</article-id><article-id pub-id-type="pmc">PMC11860558</article-id>
<article-id pub-id-type="doi">10.3390/toxins17020091</article-id><article-id pub-id-type="publisher-id">toxins-17-00091</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>The Role of Botulinum Toxin for Masseter Muscle Hypertrophy: A Comprehensive Review</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1878-4694</contrib-id><name><surname>Ferrillo</surname><given-names>Martina</given-names></name><xref rid="af1-toxins-17-00091" ref-type="aff">1</xref><xref rid="c1-toxins-17-00091" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Sommadossi</surname><given-names>Eleonora</given-names></name><xref rid="af2-toxins-17-00091" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0564-2320</contrib-id><name><surname>Raciti</surname><given-names>Loredana</given-names></name><xref rid="af3-toxins-17-00091" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9221-2497</contrib-id><name><surname>Calafiore</surname><given-names>Dario</given-names></name><xref rid="af4-toxins-17-00091" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Mezian</surname><given-names>Kamal</given-names></name><xref rid="af5-toxins-17-00091" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Tarantino</surname><given-names>Valeria</given-names></name><xref rid="af6-toxins-17-00091" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5254-3283</contrib-id><name><surname>Vecchio</surname><given-names>Michele</given-names></name><xref rid="af7-toxins-17-00091" ref-type="aff">7</xref><xref rid="af8-toxins-17-00091" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4063-9821</contrib-id><name><surname>Longo</surname><given-names>Umile Giuseppe</given-names></name><xref rid="af9-toxins-17-00091" ref-type="aff">9</xref><xref rid="af10-toxins-17-00091" ref-type="aff">10</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9105-1839</contrib-id><name><surname>Losco</surname><given-names>Luigi</given-names></name><xref rid="af11-toxins-17-00091" ref-type="aff">11</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5541-8346</contrib-id><name><surname>de Sire</surname><given-names>Alessandro</given-names></name><xref rid="af12-toxins-17-00091" ref-type="aff">12</xref><xref rid="af13-toxins-17-00091" ref-type="aff">13</xref><xref rid="af14-toxins-17-00091" ref-type="aff">14</xref></contrib></contrib-group><aff id="af1-toxins-17-00091"><label>1</label>Dentistry Unit, Department of Health Sciences, University of Catanzaro &#x0201c;Magna Graecia&#x0201d;, 88100 Catanzaro, Italy</aff><aff id="af2-toxins-17-00091"><label>2</label>Private Practice, 10121 Turin, Italy; <email>sommadossi.e@gmail.com</email></aff><aff id="af3-toxins-17-00091"><label>3</label>Unit&#x000e0; Spinale Unipolare, Azienda Ospedaliera per le Emergenze Cannizzaro, 98102 Catania, Italy; <email>loredana.raciti79@gmail.com</email></aff><aff id="af4-toxins-17-00091"><label>4</label>Physical Medicine and Rehabilitation Unit, Department of Neurosciences, ASST Carlo Poma, 46100 Mantova, Italy; <email>dario.calafiore@asst-mantova.it</email></aff><aff id="af5-toxins-17-00091"><label>5</label>Department of Rehabilitation Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, 12800 Prague, Czech Republic; <email>kamal.mezian@lf1.cuni.cz</email></aff><aff id="af6-toxins-17-00091"><label>6</label>Private Practice, 90142 Palermo, Italy; <email>tarantinov4@gmail.com</email></aff><aff id="af7-toxins-17-00091"><label>7</label>Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy; <email>michele.vecchio@unict.it</email></aff><aff id="af8-toxins-17-00091"><label>8</label>Rehabilitation Unit, &#x0201c;AOU Policlinico G. Rodolico-San Marco&#x0201d;, 95123 Catania, Italy</aff><aff id="af9-toxins-17-00091"><label>9</label>Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo 200, 00128 Roma, Italy; <email>g.longo@policlinicocampus.it</email></aff><aff id="af10-toxins-17-00091"><label>10</label>Research Unit of Orthopaedic and Trauma Surgery, Department of Medicine and Surgery, Universit&#x000e0; Campus Bio-Medico di Roma, Via Alvaro del Portillo 21, 00128 Roma, Italy</aff><aff id="af11-toxins-17-00091"><label>11</label>Department of Medicine, Surgery and Dentistry, University of Salerno, 84081 Baronissi, Salerno, Italy; <email>llosco@unisa.it</email></aff><aff id="af12-toxins-17-00091"><label>12</label>Physical Medicine and Rehabilitation, Department of Medical and Surgical Sciences, University of Catanzaro &#x0201c;Magna Graecia&#x0201d;, 88100 Catanzaro, Italy; <email>alessandro.desire@unicz.it</email></aff><aff id="af13-toxins-17-00091"><label>13</label>Research Center on Musculoskeletal Health, MusculoSkeletalHealth@UMG, University of Catanzaro &#x0201c;Magna Graecia&#x0201d;, 88100 Catanzaro, Italy</aff><aff id="af14-toxins-17-00091"><label>14</label>Department of Rehabilitation and Sports Medicine, Second Faculty of Medicine, Charles University and University Hospital Motol, 15006 Prague, Czech Republic</aff><author-notes><corresp id="c1-toxins-17-00091"><label>*</label>Correspondence: <email>martina.ferrillo@unicz.it</email></corresp></author-notes><pub-date pub-type="epub"><day>14</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>17</volume><issue>2</issue><elocation-id>91</elocation-id><history><date date-type="received"><day>07</day><month>1</month><year>2025</year></date><date date-type="rev-recd"><day>03</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>05</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Masticatory muscle hypertrophy (MMH) is a rare clinical phenomenon of uncertain etiology, characterized by a soft swelling near the angle of the jaw. This abnormal enlargement of the masseter muscle can alter the facial profile, leading to aesthetic concerns. Moreover, MMH may also have significant functional repercussions, including pain in the masseter region, often associated with temporomandibular disorders, fatigue, and discomfort during mastication. Non-conservative approaches offer an effective and minimally invasive solution by inducing localized muscle relaxation and reducing hypertrophy. Botulinum neurotoxin type A (BoNT/A) represents a therapeutic option for managing MMH, considering that injections can effectively reduce the masseter muscle volume, improving both facial aesthetics and related symptoms. Currently, the standard non-surgical management of MMH is BoNT/A injections, although consensus on the average dosage has not been definitely reached; on the other hand, there are data available in the literature about the injection technique of BoNT/A for lower face contouring. Therefore, the present comprehensive review aimed at exploring in detail the role of BoNT/A in the treatment of masseter muscle hypertrophy, describing its mechanism of action, the administration protocols, the clinical effects, and any side effects.</p></abstract><kwd-group><kwd>masseter muscle hypertrophy</kwd><kwd>lower face contouring</kwd><kwd>botulinum toxin type A</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-toxins-17-00091"><title>1. Introduction</title><p>The masseter muscle is one of the primary muscles of mastication and plays a crucial role in mandibular movement and masticatory function. However, under certain circumstances, there can be an uncommon condition characterized by an abnormal increase in its size, defined as &#x0201c;masticatory muscle hypertrophy&#x0201d; (MMH) [<xref rid="B1-toxins-17-00091" ref-type="bibr">1</xref>]. MMH has a high incidence in the second and third decades of life, with no sex predilection, can occur unilaterally or more commonly bilaterally (in about 60% of cases) [<xref rid="B2-toxins-17-00091" ref-type="bibr">2</xref>,<xref rid="B3-toxins-17-00091" ref-type="bibr">3</xref>], and although the condition is generally benign, can significantly impact both aesthetics and function [<xref rid="B4-toxins-17-00091" ref-type="bibr">4</xref>]. Functional problems may manifest as protrusion of the jaw, pain, or headache [<xref rid="B5-toxins-17-00091" ref-type="bibr">5</xref>]. The exact etiology remains unclear; however, it is most regarded as an adaptive response to chronic functional stimuli or repeated muscle stress [<xref rid="B5-toxins-17-00091" ref-type="bibr">5</xref>]. Contributing factors such as masticatory habits&#x02014;including excessive gum chewing, clenching, and bruxism&#x02014;or genetic predispositions have been reported [<xref rid="B6-toxins-17-00091" ref-type="bibr">6</xref>]. When no specific etiological factors can be identified, an idiopathic origin should be considered (IMMH) [<xref rid="B7-toxins-17-00091" ref-type="bibr">7</xref>]. Notably, certain conditions such as psychological disorders or emotional disturbances for developing IMMH have been identified; these risk factors alter proprioception and affect the ability to maintain proper tone in the masseter muscle [<xref rid="B2-toxins-17-00091" ref-type="bibr">2</xref>].</p><p>From an aesthetic perspective, MMH can significantly alter the facial profile by enlargement of the masseter and/or temporalis muscles, often leading to functional and aesthetic concerns. The increase in muscle volume can give the mandible a squared and angular appearance, affecting the perception of facial symmetry and harmony. This aesthetic effect often concerns patients, prompting them to seek treatments to improve their facial appearance [<xref rid="B8-toxins-17-00091" ref-type="bibr">8</xref>]. MMH can have significant functional repercussions. Patients may report localized pain in the masseter region, often associated with temporomandibular disorders (TMDs). Patients may also experience fatigue or discomfort during mastication due to increased muscle tension and altered biomechanics [<xref rid="B2-toxins-17-00091" ref-type="bibr">2</xref>].</p><p>This condition can impair masticatory efficiency and contribute to worsening TMDs, further exacerbating discomfort or chronic muscle tension [<xref rid="B9-toxins-17-00091" ref-type="bibr">9</xref>,<xref rid="B10-toxins-17-00091" ref-type="bibr">10</xref>,<xref rid="B11-toxins-17-00091" ref-type="bibr">11</xref>]. In some cases, excessive muscle activity can impair masticatory function, causing difficulty in mandibular movements and contributing to bruxism [<xref rid="B4-toxins-17-00091" ref-type="bibr">4</xref>]. Diagnosis of unilateral MMH could be made based on clinical examination and radiological findings [<xref rid="B2-toxins-17-00091" ref-type="bibr">2</xref>]. The treatment of MMH varies depending on the severity of the condition and the patient&#x02019;s needs. Conservative treatments&#x02014;such as the use of occlusal splints or night guards, oral devices to reduce muscle activity during sleep, physiotherapy as muscle massages and relaxation techniques to alleviate muscle tension, and behavior modification&#x02014;aim to alleviate symptoms by reducing muscle hyperactivity and stress such as teeth grinding and excessive chewing of gum [<xref rid="B6-toxins-17-00091" ref-type="bibr">6</xref>,<xref rid="B12-toxins-17-00091" ref-type="bibr">12</xref>,<xref rid="B13-toxins-17-00091" ref-type="bibr">13</xref>]. Non-conservative approaches, including botulinum toxin injections, offer an effective and minimally invasive solution by inducing localized muscle relaxation and reducing hypertrophy [<xref rid="B14-toxins-17-00091" ref-type="bibr">14</xref>]. More in detail, botulinum neurotoxin type A (BoNT/A) represents a known therapeutic option for managing MMH considering that injections can effectively reduce the masseter muscle volume, improving both facial aesthetics and related symptoms [<xref rid="B6-toxins-17-00091" ref-type="bibr">6</xref>,<xref rid="B8-toxins-17-00091" ref-type="bibr">8</xref>,<xref rid="B14-toxins-17-00091" ref-type="bibr">14</xref>,<xref rid="B15-toxins-17-00091" ref-type="bibr">15</xref>]. The effect duration is temporary, requiring repeated treatments, but it offers a minimally invasive solution with a low risk of complications. Botulinum toxin type A (BoNT/A) injections are currently the standard non-surgical treatment for masseter muscle hypertrophy (MMH); however, a definitive consensus on the average dosage has yet to be established. Nevertheless, the literature provides substantial data on BoNT/A injection techniques for lower face contouring [<xref rid="B14-toxins-17-00091" ref-type="bibr">14</xref>,<xref rid="B16-toxins-17-00091" ref-type="bibr">16</xref>,<xref rid="B17-toxins-17-00091" ref-type="bibr">17</xref>].</p><p>Therefore, the present comprehensive review aimed at exploring in detail the role of BoNT/A in the treatment of masseter muscle hypertrophy, describing its mechanism of action, the administration protocols, the clinical effects, and any side effects.</p></sec><sec sec-type="methods" id="sec2-toxins-17-00091"><title>2. Methods</title><p>Articles were selected through a comprehensive literature search in databases such as PubMed, Scopus, and Web of Science. The search strategy included keywords such as &#x0201c;botulinum toxin&#x0201d;, &#x0201c;masseter muscle hypertrophy&#x0201d;, &#x0201c;mechanism of action&#x0201d;, &#x0201c;side effects&#x0201d;, and &#x0201c;treatment outcomes.&#x0201d; Inclusion criteria focused on studies published in peer-reviewed journals, primarily in English, and addressing the clinical applications, mechanism of action, or side effects of the botulinum toxin in masseter hypertrophy. Exclusion criteria included case reports and studies with insufficient data.</p></sec><sec id="sec3-toxins-17-00091"><title>3. Masseter Muscle Hypertrophy</title><p>MMH is a rare clinical phenomenon of uncertain etiology [<xref rid="B18-toxins-17-00091" ref-type="bibr">18</xref>], characterized by a soft swelling near the angle of the jaw, which may be associated with facial pain, significantly impacting facial aesthetics and functionality [<xref rid="B19-toxins-17-00091" ref-type="bibr">19</xref>]. It can affect one side or both sides of the face and is characterized by an increase in the volume of muscle tissue, resulting in a change in the contour of the face [<xref rid="B20-toxins-17-00091" ref-type="bibr">20</xref>]. In the literature, MMH is often described as a condition concomitant with the hypertrophy of other masticatory muscles, such as the temporalis muscles [<xref rid="B21-toxins-17-00091" ref-type="bibr">21</xref>] or even medial pterygoid muscles [<xref rid="B22-toxins-17-00091" ref-type="bibr">22</xref>]. Bilateral widening of the masseter muscles is more common but constitutes a minor aesthetic problem while maintaining facial symmetry [<xref rid="B21-toxins-17-00091" ref-type="bibr">21</xref>]. Although the exact etiology of acquired hypertrophy of the masseter muscle is not well-known, there are several factors associated with its development, including the following: bruxism, TMD, pain, emotional stress, and oral parafunctions, including excessive unilateral chewing [<xref rid="B6-toxins-17-00091" ref-type="bibr">6</xref>,<xref rid="B22-toxins-17-00091" ref-type="bibr">22</xref>,<xref rid="B23-toxins-17-00091" ref-type="bibr">23</xref>,<xref rid="B24-toxins-17-00091" ref-type="bibr">24</xref>]. A recent study has demonstrated that intensive gum chewing can increase the stiffness of the masseter muscle and lead to bilateral hypertrophy of the masseter [<xref rid="B25-toxins-17-00091" ref-type="bibr">25</xref>]. On the other hand, findings from several researchers suggest that the increase in muscle size is not caused by work-related hypertrophy but is the result of compensatory enlargement due to the lack of a specific type of muscle fiber [<xref rid="B26-toxins-17-00091" ref-type="bibr">26</xref>]. Furthermore, along with the increase in muscle mass, changes may occur in the adjacent bone tissue, such as a thickening of the cortex of the angle and ramus of the mandible, the temporal fossa, and the zygomatic arch with a corresponding decrease in the area of the medulla or prominent exostoses at the angle of the mandibular bone, visible on computed tomography (CT) scans [<xref rid="B27-toxins-17-00091" ref-type="bibr">27</xref>]. Bilateral enlargement of the masseter muscles is often accompanied by pain, which may be intermittent and may be confused with pain arising from the parotid gland [<xref rid="B28-toxins-17-00091" ref-type="bibr">28</xref>,<xref rid="B29-toxins-17-00091" ref-type="bibr">29</xref>]. Clinical examination usually reveals a mass of soft tissue near to the angle of the jaw, which becomes more prominent when clenching the teeth [<xref rid="B30-toxins-17-00091" ref-type="bibr">30</xref>]. A limitation of mouth opening has been reported in some cases, particularly when the muscles are focally dystonic with tension in the region of the hypertrophic muscle [<xref rid="B31-toxins-17-00091" ref-type="bibr">31</xref>]. It should be noted that the composition of muscle fibers in the enlarged masseter is very different from similar &#x0201c;work hypertrophy&#x0201d; muscles and healthy masseter muscles [<xref rid="B32-toxins-17-00091" ref-type="bibr">32</xref>], suggesting that the term &#x0201c;hypertrophy&#x0201d; may be potentially misleading. Most patients report a slow but progressive nature of the condition [<xref rid="B22-toxins-17-00091" ref-type="bibr">22</xref>,<xref rid="B27-toxins-17-00091" ref-type="bibr">27</xref>]. The pathophysiology of muscle tone in patients with masseter muscle hypertrophy has not been studied. The increase in masticatory muscle tone is related to the increase in masticatory forces, generated by the masticatory muscles [<xref rid="B14-toxins-17-00091" ref-type="bibr">14</xref>]. Both parameters increase negatively during parafunction, which means harmful movement habits (such as grinding, clenching, or chattering teeth, biting nails, pressing the tongue against the teeth, and frequently chewing gum) that do not relate to physiological activities [<xref rid="B33-toxins-17-00091" ref-type="bibr">33</xref>]. Stal et al. [<xref rid="B34-toxins-17-00091" ref-type="bibr">34</xref>] pointed out that there is a different reactivity of masticatory muscles and skeletal muscles to stress because both these muscle groups have different embryonic origins; the masticatory muscles come from the mesenchyme of the first pharyngeal arch, while the skeletal muscles come from the mesoderm of the somite called the myotome, and Korfage et al. [<xref rid="B35-toxins-17-00091" ref-type="bibr">35</xref>] highlighted the important advantage of diversity of fiber types, such as that observed in jaw muscles. Indeed, compared to the muscles of the limbs and trunk, the masticatory muscles possess a higher percentage of hybrid fibers, which express many subtypes of myosin or a greater number of type I fibers [<xref rid="B36-toxins-17-00091" ref-type="bibr">36</xref>]. A large amount of hybrid fibers is associated with the plasticity of masticatory muscles and more efficient energy consumption during contraction [<xref rid="B37-toxins-17-00091" ref-type="bibr">37</xref>]. Compared to the masticatory muscles, limb and trunk muscles have type II fibers with a larger diameter than type I. This suggests that the high presence of type I fibers with a small cross-sectional area (CSA) in masticatory muscles could facilitate the greater exchange of nutrients and O<sub>2</sub> with the extracellular environment, increasing the fibers&#x02019; resistance to fatigue [<xref rid="B38-toxins-17-00091" ref-type="bibr">38</xref>]. Excessive and prolonged muscle tension becomes the cause of non-physiological and excessive overload of the TMJ, which in turn leads to damage to the soft tissue elements inside the joints [<xref rid="B39-toxins-17-00091" ref-type="bibr">39</xref>].</p></sec><sec id="sec4-toxins-17-00091"><title>4. Botulinum Toxin: Mechanisms of Action and Indications</title><p>Botulinum toxin is a neurotoxin produced by the anaerobic bacterium <italic toggle="yes">Clostridium botulinum</italic>, consisting of a neurotoxic core and non-toxic proteins. There are seven serotypes of BT (A, B, C, D, E, F, and G), each of which has additional subtypes (e.g., subtype A contains several distinct subtypes). The growing use of botulinum neurotoxins (BoNTs) in medical and aesthetic applications has spurred the development of various BoNT products [<xref rid="B40-toxins-17-00091" ref-type="bibr">40</xref>]. All serotypes have a similar chemical structure and are neurotoxins, except for subtype C2, which belongs to the family of binary AB-type toxins, structurally composed of separate enzymatic (A, C2I) and binding (B, C2II) components [<xref rid="B41-toxins-17-00091" ref-type="bibr">41</xref>]. </p><p>Among its seven serotypes, the BoNT/A is the most extensively studied and clinically applied, particularly in aesthetic medicine, oncology, neurology, rehabilitation, and dentistry [<xref rid="B42-toxins-17-00091" ref-type="bibr">42</xref>,<xref rid="B43-toxins-17-00091" ref-type="bibr">43</xref>,<xref rid="B44-toxins-17-00091" ref-type="bibr">44</xref>,<xref rid="B45-toxins-17-00091" ref-type="bibr">45</xref>]. Differences among the botulinum toxin serotypes lie in their specific protein targets and clinical applications. For instance, BoNT/A and BoNT/B target distinct proteins in the SNARE complex; while BoNT/A cleaves the SNAP-25 protein, BoNT/B specifically targets synaptobrevin (VAMP), another critical component of the vesicle fusion machinery. This distinction contributes to their unique pharmacological profiles. BoNT/A is the primary choice for aesthetic and neurological applications due to its well-characterized safety and efficacy, whereas BoNT/B is sometimes preferred in cases of resistance to BoNT/A, such as in cervical dystonia, where its alternative protein target may overcome immunogenicity issues [<xref rid="B45-toxins-17-00091" ref-type="bibr">45</xref>,<xref rid="B46-toxins-17-00091" ref-type="bibr">46</xref>,<xref rid="B47-toxins-17-00091" ref-type="bibr">47</xref>].</p><p>Upon injection, BoNT/A is endocytosed into the cell and cleaves the C-terminal portion of SNAP-25. This cleavage disrupts the SNARE complex, blocking the exocytosis of neurotransmitters and the acetylcholine release [<xref rid="B48-toxins-17-00091" ref-type="bibr">48</xref>]. Additionally, BoNT/A suppresses the peripheral release of neuropeptides and inflammatory mediators, including CGRP (calcitonin gene-related peptide), which plays a key role in pain signaling and inflammation [<xref rid="B49-toxins-17-00091" ref-type="bibr">49</xref>,<xref rid="B50-toxins-17-00091" ref-type="bibr">50</xref>,<xref rid="B51-toxins-17-00091" ref-type="bibr">51</xref>]. The reduction in CGRP in the peripheral and central nervous system is thought to contribute to its therapeutic effects in migraine management [<xref rid="B41-toxins-17-00091" ref-type="bibr">41</xref>,<xref rid="B52-toxins-17-00091" ref-type="bibr">52</xref>,<xref rid="B53-toxins-17-00091" ref-type="bibr">53</xref>]. CGRP release occurs in the meninges and the trigeminal caudal nucleus and is amplified by P2Y purinergic receptors on satellite glial cells [<xref rid="B54-toxins-17-00091" ref-type="bibr">54</xref>], which are influenced by factors such as 17-beta-estradiol. Conversely, P2X3 receptor-mediated peripheral pain signaling in neuronal afferents can attenuate CGRP activity [<xref rid="B55-toxins-17-00091" ref-type="bibr">55</xref>]. Furthermore, receptors such as the transient receptor potential vanilloid 1 (TRPV1) play a critical role in pain perception and sensitization. These receptors may represent additional therapeutic targets for pain management [<xref rid="B56-toxins-17-00091" ref-type="bibr">56</xref>]. The toxin consists of a 100 kDa heavy chain (HC) and a 50 kDa light chain (LC) linked by a disulfide bond. The heavy chain facilitates receptor binding and endocytosis into the neuron, while the light chain cleaves SNAP-25&#x02014;a component of the SNARE complex&#x02014;to inhibit acetylcholine release at the neuromuscular junction. This process leads to a reversible flaccid paralysis, a key therapeutic mechanism in conditions like spasticity, dystonia, and migraine.</p><p>BoNT/A has demonstrated significant effects in treating MMH, bruxism, TMDs, and oromandibular dystonia, especially in terms of function recovery [<xref rid="B57-toxins-17-00091" ref-type="bibr">57</xref>]. Indeed, intra-muscular injections into the masseter and anterior temporalis muscles reduce muscle tone and bulk, alleviating pain and improving jaw functionality. The therapeutic effect of intramuscular injections depends on the section of the muscle, the dose administered, and the injection method [<xref rid="B58-toxins-17-00091" ref-type="bibr">58</xref>,<xref rid="B59-toxins-17-00091" ref-type="bibr">59</xref>]. Electromyographic studies confirm the decreased neuromuscular activity post-injection, with effects lasting 3&#x02013;4 months [<xref rid="B49-toxins-17-00091" ref-type="bibr">49</xref>,<xref rid="B59-toxins-17-00091" ref-type="bibr">59</xref>]. Additionally, the reduced formation of axonal bundles during recovery promotes sustained muscle relaxation, enhancing therapeutic outcomes [<xref rid="B60-toxins-17-00091" ref-type="bibr">60</xref>]. In neurology, BoNT/A has become a cornerstone therapy for chronic migraine. By targeting CGRP release in the trigeminal system and modulating pain transmission pathways, the toxin offers a dual benefit&#x02014;reducing nociceptive signaling and peripheral sensitization. Emerging studies also suggest that receptors like TRPV1 and purinergic P2X3 may represent complementary targets in pain management, further broadening the therapeutic potential of BoNT-A [<xref rid="B52-toxins-17-00091" ref-type="bibr">52</xref>,<xref rid="B56-toxins-17-00091" ref-type="bibr">56</xref>].</p></sec><sec id="sec5-toxins-17-00091"><title>5. How to Treat a &#x0201c;Square Face&#x0201d;: Role of Botulinum Toxin</title><p>BoNT/A is the most popular subtype for injection for aesthetic purposes. To date, botulinum toxin has been widely and mainly used for the treatment of conditions affecting the upper and middle face; however, due to recent efforts and patients&#x02019; needs, the indications for cosmetic reasons of botulinum toxin injection have been expanded to the lower face and neck areas [<xref rid="B59-toxins-17-00091" ref-type="bibr">59</xref>]. The use of botulinum toxin for the aesthetic contouring of the lower face is extending, and it is typically achieved by injecting the masseter muscle.</p><p>The most common cosmetic complaint for which patients seek treatment is a &#x0201d;square face&#x0201d;, and the solution is the injection of botulinum toxin into the abovementioned muscle to decrease muscle hypertrophy. A triangular-shaped lower part of the face with a perfect jawline is the most desired shape by women compared to a wide and square one, which for many is considered more attractive in males. The aesthetics of the lower third of the face is determined by three main factors: size of the bony jaw, mass of the masseter muscle, and volume of the subcutaneous adipose tissue [<xref rid="B60-toxins-17-00091" ref-type="bibr">60</xref>]. The size and shape of the jaw are predetermined at birth and are fixed at adulthood; these factors also vary between different ethnicities and races. The volume of subcutaneous fat varies from person to person based on their individual body mass index and can change over time, according to general health and body fat percentage [<xref rid="B60-toxins-17-00091" ref-type="bibr">60</xref>]. Masseter hypertrophy can result in a wide jaw, which negatively affects the aesthetic appearance of patients [<xref rid="B61-toxins-17-00091" ref-type="bibr">61</xref>]. The procedure is performed by injection with a 30 G needle inserted deep into the muscle; the injection safety zone can be easily determined. The inferior border of the mandible is marked, which is the lower margin of the injection zone; the upper margin is a line drawn from the corner of the mouth to the earlobe. The patients are asked to grit the teeth so that the anterior and posterior borders of the masseter muscle can be palpated and marked. Thus, a rectangle shape is drawn on the lower face, and the injection safety zone is depicted within this rectangle, 1 cm from the margins [<xref rid="B61-toxins-17-00091" ref-type="bibr">61</xref>]. Operating within this area, recommendations most commonly suggest three injection points, using a total amount of 24 to 60 U of onabotulinumtoxinA or incobotulinumtoxinA and 60 to 300 U of abobotulinumtoxinA [<xref rid="B60-toxins-17-00091" ref-type="bibr">60</xref>,<xref rid="B61-toxins-17-00091" ref-type="bibr">61</xref>]. Chang et al. [<xref rid="B62-toxins-17-00091" ref-type="bibr">62</xref>] have reported a favorable long-term efficacy for this method, with a 12% reduction in masseteric muscle volume after three consecutive injections, 1 year after completion of the treatment. The minimum dosage used in a previous study for toxin injection into the masseters was 20 U of onabotulinumtoxinA on each side with two injection sessions at a 4-month interval [<xref rid="B63-toxins-17-00091" ref-type="bibr">63</xref>]. The standard non-surgical treatment for MMH currently involves BoNT/A injections; however, there is no definitive consensus on the average dosage. Nevertheless, the existing literature provides valuable insights into the injection techniques of BoNT/A for achieving lower face contouring [<xref rid="B64-toxins-17-00091" ref-type="bibr">64</xref>,<xref rid="B65-toxins-17-00091" ref-type="bibr">65</xref>,<xref rid="B66-toxins-17-00091" ref-type="bibr">66</xref>].</p><p>While some authors argue that a multi-point injection allows for better distribution of the toxin into the muscle, single-point injections are quicker to perform and less painful, and may be less prone to producing complications [<xref rid="B67-toxins-17-00091" ref-type="bibr">67</xref>]. In contrast, in 2018, Nikolis et al. [<xref rid="B68-toxins-17-00091" ref-type="bibr">68</xref>] evaluated the effectiveness of two injection techniques in the treatment of 30 patients with MMH using the toxin incobotulinumtoxinA. Fifteen patients received 40U of incobotulinumtoxinA at a single injection point and fifteen patients received 40U with a 5-injection technique (8U for each injection). At the 6-month follow-up, they demonstrated no significant difference between the two injection techniques. It has been proven that botulinum toxin is a safe treatment, even after repeated sessions for several years. However, in most cases, there is a need for using a combination of botulinum toxin injection with other procedures to obtain optimal results [<xref rid="B66-toxins-17-00091" ref-type="bibr">66</xref>,<xref rid="B67-toxins-17-00091" ref-type="bibr">67</xref>]. An example of combination therapy would be fat grafting/autologous fat grafting with botulinum toxin injection into the masseters as a safe and satisfactory method for short and wide faces in order to normalize the ratios of different areas of the lower face and obtain a desirable oval face [<xref rid="B69-toxins-17-00091" ref-type="bibr">69</xref>].</p></sec><sec id="sec6-toxins-17-00091"><title>6. Role of Botulinum Toxin for Masseter Muscle Hypertrophy</title><p>Recently, the scientific literature has revealed a higher interest regarding the effectiveness and safety of BoNT/A, highlighting its potential as a non-invasive therapeutic option in masseter muscle hypertrophy [<xref rid="B70-toxins-17-00091" ref-type="bibr">70</xref>]. A recent review performed by Kundu et al. [<xref rid="B60-toxins-17-00091" ref-type="bibr">60</xref>] analyzed the effect of BoNT/A in masseter muscle, stating that botulinum toxin was consistently effective in relieving pain at 3 and 6 months after treatment with an effect that is probably dose-dependent. BoNT/A was consistently effective in relieving pain 3 and 6 months after treatment [<xref rid="B59-toxins-17-00091" ref-type="bibr">59</xref>,<xref rid="B60-toxins-17-00091" ref-type="bibr">60</xref>]. It is well-demonstrated that for each unit of increase in the dose of BoNT/A, the severity of masseteric hypertrophy decreased in terms of pain [<xref rid="B62-toxins-17-00091" ref-type="bibr">62</xref>,<xref rid="B69-toxins-17-00091" ref-type="bibr">69</xref>,<xref rid="B70-toxins-17-00091" ref-type="bibr">70</xref>]. A recent study has demonstrated that a single injection in masseter muscle seems to have a clinically subjective and objective effect on masseteric hypertrophy [<xref rid="B69-toxins-17-00091" ref-type="bibr">69</xref>,<xref rid="B70-toxins-17-00091" ref-type="bibr">70</xref>]. Furthermore, patients who received three injections experienced a higher efficacy and longer duration of treatment maintenance compared with those who received two injections [<xref rid="B71-toxins-17-00091" ref-type="bibr">71</xref>]. Several techniques of injecting BoNT/A into masseter muscle have been employed in the past. Some authors are used to the multi-point injection technique since it allows for a better distribution of the toxin in the muscle, while some use the lowest injection sites possible or a single injection site [<xref rid="B69-toxins-17-00091" ref-type="bibr">69</xref>]. Moreover, several studies demonstrated the efficacy of a biphasic injection method that is associated with minimum self-resolving side effects [<xref rid="B72-toxins-17-00091" ref-type="bibr">72</xref>,<xref rid="B73-toxins-17-00091" ref-type="bibr">73</xref>,<xref rid="B74-toxins-17-00091" ref-type="bibr">74</xref>,<xref rid="B75-toxins-17-00091" ref-type="bibr">75</xref>]. The authors proved the role of extensive knowledge of muscular anatomy and an appropriate injection technique as key factors in desirable clinical outcomes and decreasing side effects [<xref rid="B75-toxins-17-00091" ref-type="bibr">75</xref>]. Nevertheless, comparing the two methods of multi-injection and single-injection treatments, no superiority of either method was found. Moreover, it has been suggested that the analgesic effect of BoNT/A could involve the reduction in neurotransmitter release at both peripheral and central levels [<xref rid="B73-toxins-17-00091" ref-type="bibr">73</xref>]. Consequently, BoNT/A may have a direct analgesic effect by blocking the transmission of pain signals from the temporomandibular area to the nervous system [<xref rid="B74-toxins-17-00091" ref-type="bibr">74</xref>]. This might be due to BoNT/A&#x02019;s ability to inhibit the release of certain neurotransmitters involved in pain signaling [<xref rid="B60-toxins-17-00091" ref-type="bibr">60</xref>].</p><p>From a rehabilitative perspective, a recent systematic review of 2024 affirms that BoNT/A can improve the masseter hypertrophy and hypertonicity, significantly alleviating joint stress and improving jaw function [<xref rid="B68-toxins-17-00091" ref-type="bibr">68</xref>]. Furthermore, several RCTs support its use for treating TMDs that can arise as a consequence of bruxism or independently [<xref rid="B75-toxins-17-00091" ref-type="bibr">75</xref>,<xref rid="B76-toxins-17-00091" ref-type="bibr">76</xref>]. The long duration of action of BoNT/A for pain relief, which can persist up to 6 months after treatment, could be due to the ability of its protease to avoid cellular degradation mechanisms and survive in the cell cytoplasm for a prolonged period [<xref rid="B60-toxins-17-00091" ref-type="bibr">60</xref>]. In fact, it has been hypothesized that the pain-relieving effect of BoNT/A persists even after the return of muscle strength [<xref rid="B77-toxins-17-00091" ref-type="bibr">77</xref>]. A potential explanation could also be that bruxists became more aware of parafunctional (teeth clenching) habits and took corrective measures, which may have restored the normal function of other masticatory muscles [<xref rid="B78-toxins-17-00091" ref-type="bibr">78</xref>]. In this context, muscle thickness of the masseter muscle can play a pivotal role in orofacial pain. The use of BoNT/A can decrease the muscle&#x02019;s thickness by an average of 31% after a 3-month follow-up, as measured by ultrasound, and volume loss continues even after restoration of the muscle function [<xref rid="B67-toxins-17-00091" ref-type="bibr">67</xref>,<xref rid="B79-toxins-17-00091" ref-type="bibr">79</xref>,<xref rid="B80-toxins-17-00091" ref-type="bibr">80</xref>,<xref rid="B81-toxins-17-00091" ref-type="bibr">81</xref>]. Recent studies showed a decrease in muscle thickness and an improvement in masseter contraction ability and masticatory performance. The authors conclude that a single injection of BoNT/A does not seem to affect muscle thickness&#x02014;assessed by ultrasound&#x02014;permanently since the thickness had recovered after 3 months [<xref rid="B69-toxins-17-00091" ref-type="bibr">69</xref>]. However, the muscle&#x02019;s thickness following a booster injection 3 months after the first did not return to normal after 6 months [<xref rid="B69-toxins-17-00091" ref-type="bibr">69</xref>]. Previous animal studies and some human studies indicate that this could be a result of incomplete re-innervation of the injected area, fatty infiltration, fibrosis, and even atrophy due to necrosis of the muscle fibers in mice and humans [<xref rid="B82-toxins-17-00091" ref-type="bibr">82</xref>]. It is interesting to note that the evaluation of muscle thickness using a caliper has shown that muscle thickness is directly proportional to the symptoms reported by the patient: after the injection, the thickness of the masseter decreases and, similarly, the symptoms disappear or are reduced [<xref rid="B67-toxins-17-00091" ref-type="bibr">67</xref>]. Moreover, facial aesthetics also improve thanks to the reduction in thickness and muscle relaxation [<xref rid="B83-toxins-17-00091" ref-type="bibr">83</xref>]. It is important to note that muscle thickness is often correlated with muscle strength. Thus, clinicians normally make dose adjustments based on the hypertrophy of the masseter muscle while avoiding the prevalence of side effects [<xref rid="B84-toxins-17-00091" ref-type="bibr">84</xref>]. Moreover, it has been stated that the human system produces antibodies when exposed to excessive BoNT/A, which may impair its effectiveness in future treatment but, to date, BoNT/A has shown a very low protein content, avoiding this limiting effect [<xref rid="B85-toxins-17-00091" ref-type="bibr">85</xref>,<xref rid="B86-toxins-17-00091" ref-type="bibr">86</xref>,<xref rid="B87-toxins-17-00091" ref-type="bibr">87</xref>]. To achieve personalized dose injections based on the ultrasound evaluation of masseter muscle and deep tendon thickness, Shi et al. [<xref rid="B88-toxins-17-00091" ref-type="bibr">88</xref>] assessed the morphological changes in the masseter muscle and deep tendon of 206 subjects under relaxed and clenched conditions using ultrasound. The study found that the deep belly was thicker in both relaxed and clenched states in longitudinal ultrasound images; however, when Li et al. [<xref rid="B18-toxins-17-00091" ref-type="bibr">18</xref>] used the same measurement method on 42 participants, they reached an opposite conclusion. Regarding muscle activity, compared to placebo injections, BoNT/A was associated with a significant decrease in occlusal force (kg) 3 months after injection, with a decrease in effects after 3 months and no significant differences at 6 months [<xref rid="B89-toxins-17-00091" ref-type="bibr">89</xref>,<xref rid="B90-toxins-17-00091" ref-type="bibr">90</xref>,<xref rid="B91-toxins-17-00091" ref-type="bibr">91</xref>,<xref rid="B92-toxins-17-00091" ref-type="bibr">92</xref>]. Comparing BoNT/A treatment with the use of occlusal bites and placebo injections, the analysis of maximum chewing force after BoNT/A injections demonstrated a significant reduction at 1 month or less. BoNT/A continued to outperform occlusal splints and saline placebo at 3 months [<xref rid="B70-toxins-17-00091" ref-type="bibr">70</xref>]. Between 3 and 6 months, a significantly higher maximum chewing force was observed in the BoNT/A group compared to the oral splinting group [<xref rid="B70-toxins-17-00091" ref-type="bibr">70</xref>]. No significant differences in maximal chewing force were observed between the BoNT/A and saline placebo groups [<xref rid="B70-toxins-17-00091" ref-type="bibr">70</xref>]. BoNT/A works by controlling the intense contractions of the masticatory muscles [<xref rid="B93-toxins-17-00091" ref-type="bibr">93</xref>]. Injection of the masseter alone is, therefore, sufficient to treat bruxism [<xref rid="B94-toxins-17-00091" ref-type="bibr">94</xref>,<xref rid="B95-toxins-17-00091" ref-type="bibr">95</xref>], with the other masticatory muscles (temporalis, pterygoids, digastrics, and genius-hyoids) capable of compensating and, therefore, supporting effective chewing [<xref rid="B96-toxins-17-00091" ref-type="bibr">96</xref>]. The favorable mechanism of neuromuscular conduction block significantly reduces the tone of the masseter muscle, as confirmed by electromyographic (EMG) evaluation [<xref rid="B97-toxins-17-00091" ref-type="bibr">97</xref>,<xref rid="B98-toxins-17-00091" ref-type="bibr">98</xref>]. Furthermore, the recovery of conductivity occurs based on the formation of new axonal bundles, which are in much smaller quantities than the original connections, a very favorable phenomenon for achieving muscle relaxation [<xref rid="B99-toxins-17-00091" ref-type="bibr">99</xref>]. In one study, post-injection polysomnographic evaluation confirmed that botulinum reduces the intensity of contraction of the masseter muscle for at least 12 weeks but does not modify the frequency of occurrence of rhythmic masticatory muscle activity (RMMA) episodes. On the other hand, the author offers a different perspective of bruxism: RMMA episodes are physiological so it is not necessary to intervene to try to reduce them and improve symptoms [<xref rid="B89-toxins-17-00091" ref-type="bibr">89</xref>,<xref rid="B98-toxins-17-00091" ref-type="bibr">98</xref>]. The efficacy of botulinum toxin treatment on the range of joint movements was observed: compared to a placebo, BoNT/A was associated with a significant increase in maximum pain-free opening (mm) 1 month after injection, and in unassisted opening (mm) at 1 month and 6 months post-injection; no difference was observed in maximum unassisted opening (mm) at 1 week or 2 months post-injection [<xref rid="B67-toxins-17-00091" ref-type="bibr">67</xref>]. Compared to the placebo, BoNT/A was associated with a significant increase in the right lateral excursion (mm) at 1 week, 1 month, and 6 months; and in the left lateral excursion (mm) at 1 week, 1 month, and 6 months [<xref rid="B67-toxins-17-00091" ref-type="bibr">67</xref>]. However, according to Asutay et al. [<xref rid="B99-toxins-17-00091" ref-type="bibr">99</xref>], changes in voluntary mouth opening did not show statistically significant differences, unlike what was studied by Sidebottom et al. [<xref rid="B100-toxins-17-00091" ref-type="bibr">100</xref>] and Guarda-Nardini et al. [<xref rid="B101-toxins-17-00091" ref-type="bibr">101</xref>]. Other studies agree on an improvement in temporomandibular muscle and joint function in patients with muscular TMD [<xref rid="B102-toxins-17-00091" ref-type="bibr">102</xref>,<xref rid="B103-toxins-17-00091" ref-type="bibr">103</xref>,<xref rid="B104-toxins-17-00091" ref-type="bibr">104</xref>,<xref rid="B105-toxins-17-00091" ref-type="bibr">105</xref>,<xref rid="B106-toxins-17-00091" ref-type="bibr">106</xref>,<xref rid="B107-toxins-17-00091" ref-type="bibr">107</xref>,<xref rid="B108-toxins-17-00091" ref-type="bibr">108</xref>]. In fact, compared to placebo injections, BoNT/A is associated with a significant post-injection reduction in rest pain intensity at 1 month, 2 months, 3 months, and 6 months from the first injection [<xref rid="B102-toxins-17-00091" ref-type="bibr">102</xref>,<xref rid="B103-toxins-17-00091" ref-type="bibr">103</xref>,<xref rid="B104-toxins-17-00091" ref-type="bibr">104</xref>]. Additionally, BoNT/A was found to be associated with a significant decrease in masseter muscle activity at 1&#x02009;month and occlusal force at 3&#x02009;months [<xref rid="B90-toxins-17-00091" ref-type="bibr">90</xref>]. Furthermore, BoNT/A resulted in a significantly greater increase in maximum pain-free mouth opening, unassisted mouth opening, and mandibular excursive movement at 1 month post-treatment [<xref rid="B102-toxins-17-00091" ref-type="bibr">102</xref>]. Furthermore, several systematic reviews assessed the use of BoNT/A therapy for myofascial pain, reporting a reduction in pain intensity in the BoNT/A groups and concluding that this treatment was slightly more effective than placebo for pain reduction but appears as effective as other conservative and rehabilitative approaches [<xref rid="B102-toxins-17-00091" ref-type="bibr">102</xref>,<xref rid="B103-toxins-17-00091" ref-type="bibr">103</xref>,<xref rid="B104-toxins-17-00091" ref-type="bibr">104</xref>,<xref rid="B105-toxins-17-00091" ref-type="bibr">105</xref>]. Thus, some authors conclude that no strong recommendations can be drawn [<xref rid="B106-toxins-17-00091" ref-type="bibr">106</xref>]. The therapeutic effect of intramuscular injections depends on the section of the muscle, the dose administered, and the injection method but the literature agrees on the duration of effects ranging from 3 to 4 months [<xref rid="B59-toxins-17-00091" ref-type="bibr">59</xref>,<xref rid="B72-toxins-17-00091" ref-type="bibr">72</xref>]. In summary, injection of a low dose of BoNT/A seems to have a clinically subjective and objective effect on masseteric hypertrophy. However, as a clinician, one must consider the possible harms that can occur with repeated injections in shorter intervals, which include impaired masticatory performance and muscle activity but also a permanent decrease in muscle thickness with consequent functional loss [<xref rid="B107-toxins-17-00091" ref-type="bibr">107</xref>]. In comparison, the effects of BoNT/A generally last 3&#x02013;6 months for aesthetic facial lines [<xref rid="B108-toxins-17-00091" ref-type="bibr">108</xref>]. The longer duration of effectiveness after treatment of the masseters compared to treatment of the facial lines may be related to dosage [<xref rid="B109-toxins-17-00091" ref-type="bibr">109</xref>].</p></sec><sec id="sec7-toxins-17-00091"><title>7. Protocols of Botulinum Toxin Injections for Masseter Muscle Hypertrophy</title><p>Currently, the standard non-surgical management of MMH is BoNT/A injections, although a consensus on the average dosage has not been definitely reached; on the other hand, there are data available in the literature about the injection technique of BoNT-A for lower face contouring [<xref rid="B14-toxins-17-00091" ref-type="bibr">14</xref>,<xref rid="B16-toxins-17-00091" ref-type="bibr">16</xref>,<xref rid="B17-toxins-17-00091" ref-type="bibr">17</xref>].</p><p>While some authors suppose that an injection in multiple injection sites allows for a better distribution of the toxin in the muscle and ensures a uniform reduction in the size of the masseter [<xref rid="B102-toxins-17-00091" ref-type="bibr">102</xref>], single-point injections are quicker to perform and less painful, and may be less prone to producing complications. The data, therefore, suggest using as few injection sites as possible until more robust evidence is presented [<xref rid="B110-toxins-17-00091" ref-type="bibr">110</xref>]. The most important concept when injecting BoNT/A into the masseter is to stay well within the confines of the muscle to avoid complications [<xref rid="B62-toxins-17-00091" ref-type="bibr">62</xref>]. The ideal injection site is the most prominent point of the swollen masseter muscle, where the appropriate nerve innervates the affected muscle [<xref rid="B66-toxins-17-00091" ref-type="bibr">66</xref>,<xref rid="B111-toxins-17-00091" ref-type="bibr">111</xref>]. The number of BoNT/A injection sites and dosages may depend on the thickness of the masseter muscle and the degree of hypertrophy [<xref rid="B66-toxins-17-00091" ref-type="bibr">66</xref>]. The superior portion of the masseter muscle is considered unsuitable for BoNT/A injection due to the location of the parotid duct and the absence of branches of the perforating nerve supplying the superficial layer of the masseter muscle [<xref rid="B111-toxins-17-00091" ref-type="bibr">111</xref>]. To ensure proper targeting, clinicians can ask patients to clench their teeth, which facilitates the identification of the hypertrophic muscle [<xref rid="B108-toxins-17-00091" ref-type="bibr">108</xref>]. A safe zone of the muscle lies below the line connecting the earlobe and the corner of the mouth, and between the posterior margin of the muscle and 1 cm after the corner of the mouth. Within this zone, most recommendations suggest using three injection points with a total dose of 24&#x02013;60 units of onabotulinumtoxinA or incobotulinumtoxinA, or 60&#x02013;300 units of abobotulinumtoxinA, delivered via a 30-gauge needle at appropriate depths into the muscle [<xref rid="B110-toxins-17-00091" ref-type="bibr">110</xref>]. Li et al. [<xref rid="B102-toxins-17-00091" ref-type="bibr">102</xref>] analyzed injection sites and the results indicated that at 6 months post-injection, BoNT/A injections to the masseter, temporalis, and pterygoid muscles were associated with greater pain reduction, while injections to the masseter muscles alone or masseter and temporalis muscles produced a smaller effect size. This suggests that broader targeting (masseter, temporalis, and pterygoid muscles vs. masseter and temporalis) may provide superior outcomes for pain management [<xref rid="B102-toxins-17-00091" ref-type="bibr">102</xref>]. Despite the variability in dosing protocols, most studies agree that doses lower than 20 units are inadequate for significant results, while higher doses (20&#x02013;40 units) yield better effects, particularly in patients with severe symptoms. The U.S. Food and Drug Administration (FDA) has approved a maximum dose of 400 units of onabotulinumtoxinA or incobotulinumtoxinA within a three-month interval. However, doses up to 600 units may not significantly increase the risk of adverse events. The neurotoxin load (in ng per 100U) varies among BoNT-A formulations: 0.73 ng/100U for onabotulinumtoxinA; 0.65 ng/100U for abobotulinumtoxinA; and 0.44 ng/100U for incobotulinumtoxinA. Consequently, the specific potency of the 150 kDa BoNT-A neurotoxin is estimated at 137 units/ng for onabotulinumtoxinA; 154 units/ng for abobotulinumtoxinA; and 227 units/ng for incobotulinumtoxinA [<xref rid="B112-toxins-17-00091" ref-type="bibr">112</xref>]. A summary of the literature about safety and maximum doses is reported in <xref rid="toxins-17-00091-t001" ref-type="table">Table 1</xref>.</p><p>The first reported case of MMH treatment, described by Moore and Woode in 1994 [<xref rid="B14-toxins-17-00091" ref-type="bibr">14</xref>], used 300 units of abobotulinumtoxinA in a 30-year-old man with TMJ dysfunction, myofascial pain syndrome, and masseter hypertrophy. The patient exhibited a slight muscle reduction for two weeks post-injection, with effects lasting six months without side effects. One of the largest studies, conducted by Kim et al. [<xref rid="B70-toxins-17-00091" ref-type="bibr">70</xref>], involved 1021 patients treated with 100&#x02013;140 units of abobotulinumtoxin A (ABO) for lower face contouring (383 patients could be followed for &#x0003e;3 months). The thickness was reduced by 31% and the maximum reduction in muscle strength was observed after 10&#x02013;12 weeks and 50% required a second injection after 4&#x02013;7 months. Then, the large-scale trial by Kim et al. [<xref rid="B70-toxins-17-00091" ref-type="bibr">70</xref>] reported consistent success using lower doses, indicating that modern approaches are increasingly effective with reduced toxin volumes. A reduction in symptoms can be achieved with doses less than 25U applied exclusively to the masseter muscles [<xref rid="B97-toxins-17-00091" ref-type="bibr">97</xref>]. However, recommendations most commonly suggest using a total amount of 24 to 60 U of onabotulinumtoxinA or incobotulinumtoxinA and 60 to 300 U of abobotulinumtoxinA at three sites, with a 30 G needle inserted deep into the muscle [<xref rid="B117-toxins-17-00091" ref-type="bibr">117</xref>]. A higher bilateral dose of 60&#x02013;100 U could instead be the optimal choice for the treatment of muscle TMD pain. Notably, a higher dose of BoNT/A resulted in greater pain reduction at 6 months compared to a lower dose [<xref rid="B102-toxins-17-00091" ref-type="bibr">102</xref>].</p></sec><sec id="sec8-toxins-17-00091"><title>8. Side Effects, Complications, and Contraindications of Botulinum Toxin for Masseter Muscle Hypertrophy</title><sec id="sec8dot1-toxins-17-00091"><title>8.1. Side Effects of Botulinum Toxin for Masseter Muscle Hypertrophy</title><p>Botulinum toxin injections into the masseter muscle are widely regarded as safe and effective for both therapeutic and aesthetic applications. BoNT/A has proven to be a safe treatment, even after repeated sessions for several years [<xref rid="B118-toxins-17-00091" ref-type="bibr">118</xref>]. All studies focus on identifying a safe injection area rather than on the specifics of the technique [<xref rid="B111-toxins-17-00091" ref-type="bibr">111</xref>]. There were favorable results by selecting the locations and depth of BoNT/A applications by clinical estimation and palpation, with few or no reports of adverse effects [<xref rid="B97-toxins-17-00091" ref-type="bibr">97</xref>]. The safe injection area is usually delimited by the lower mandibular border, the margins of the anterior and posterior masseter, and the zygomatic arch as the upper limit. Various side effects (intended as predictable, generally mild, and often dose-dependent outcomes of treatment) associated with the procedure have been reported, most likely secondary to excessive infiltration or inaccurate placement of the BoNT/A, albeit up to 50% of patients may experience adverse events (as harmful and unintended outcomes, which may range from mild to severe and may not always be directly linked to the treatment), which are mostly mild, transient, and self-resolving within 1&#x02013;2 months [<xref rid="B119-toxins-17-00091" ref-type="bibr">119</xref>]. <xref rid="toxins-17-00091-t002" ref-type="table">Table 2</xref> depicts the main side effects of BoNT/A for MMH management [<xref rid="B51-toxins-17-00091" ref-type="bibr">51</xref>,<xref rid="B71-toxins-17-00091" ref-type="bibr">71</xref>,<xref rid="B77-toxins-17-00091" ref-type="bibr">77</xref>,<xref rid="B82-toxins-17-00091" ref-type="bibr">82</xref>,<xref rid="B107-toxins-17-00091" ref-type="bibr">107</xref>,<xref rid="B118-toxins-17-00091" ref-type="bibr">118</xref>,<xref rid="B120-toxins-17-00091" ref-type="bibr">120</xref>,<xref rid="B121-toxins-17-00091" ref-type="bibr">121</xref>,<xref rid="B122-toxins-17-00091" ref-type="bibr">122</xref>,<xref rid="B123-toxins-17-00091" ref-type="bibr">123</xref>].</p><p>The most common complications of injections (as unintended and often preventable deviations from the expected course of treatment) include mild pain at injection sites or temporary muscle weakness (e.g., atonia of the injected muscle), which can lead to unwanted weakness or functional limitations such as reduced chewing strength and difficulty opening the mouth [<xref rid="B124-toxins-17-00091" ref-type="bibr">124</xref>]. Aesthetic concerns include asymmetry of the smile&#x02014;particularly in facial applications&#x02014;problems opening the mouth, bruising (accounting for 2.5%), incipient sagging of the cheeks and skin, local pain at the injection site, mild headache, awkward facial expressions, speech disorders, irregular swelling of the muscles, sunken cheeks, and herniation of the parotid gland through the overlying attenuated muscle. After treatment, due to the rapid reduction in size of the masseter muscle, sagging of the skin and soft tissue in the jaw area may occur in 0.2% to 2.3% of patients, resulting in a blurred and more aged appearance of the jaw [<xref rid="B75-toxins-17-00091" ref-type="bibr">75</xref>]. These are particularly common in older patients or those with thinner skin as rapid masseter muscle atrophy can lead to skin laxity of the soft tissues of the mandibular border and a more aged appearance [<xref rid="B14-toxins-17-00091" ref-type="bibr">14</xref>]. This is mainly caused by gravity and the tensile force of the platysma muscle [<xref rid="B72-toxins-17-00091" ref-type="bibr">72</xref>]. Treatment strategies to mitigate these side effects include lower doses and spaced sessions as well as complementary injections into depressor muscles to counteract sagging [<xref rid="B65-toxins-17-00091" ref-type="bibr">65</xref>]. These effects are often dose-dependent, localized, and uncommon [<xref rid="B107-toxins-17-00091" ref-type="bibr">107</xref>] and can be minimized by employing precise injection techniques and tailoring the dosage to individual patient anatomy and needs [<xref rid="B51-toxins-17-00091" ref-type="bibr">51</xref>,<xref rid="B125-toxins-17-00091" ref-type="bibr">125</xref>]. Furthermore, since the effect of BoNT/A is reversible, muscle weakness gradually recovers over the course [<xref rid="B84-toxins-17-00091" ref-type="bibr">84</xref>]. Functional side effects include transient facial asymmetry and altered chewing mechanics, which can result from unintended weakening of adjacent muscles such as the risorius or zygomaticus. Two patients in the study by Kim et al. [<xref rid="B70-toxins-17-00091" ref-type="bibr">70</xref>] reported aesthetic changes in their smile, which may be due to the diffusion of botulinum toxin toward the zygomaticus and risoris muscles during application. To avoid this, the BoNT/A must be injected well within the confines of the masseter muscle and, superiorly, a line joining the tragus to the oral commissure must be considered as the superior margin.</p></sec><sec id="sec8dot2-toxins-17-00091"><title>8.2. Complications of Botulinum Toxin for Masseter Muscle Hypertrophy</title><p>BoNT-A is widely regarded as a safe and effective therapeutic agent, yet rare complications, though infrequent, demand attention and careful management. Occasionally, paradoxical muscle swelling may occur, presenting as localized bulging despite the intended reduction in muscle activity. This phenomenon is often linked to uneven toxin diffusion or anatomical barriers, such as the deep inferior tendon within the masseter muscle. Ultrasound guidance and carefully distributed injections are key to preventing such outcomes [<xref rid="B126-toxins-17-00091" ref-type="bibr">126</xref>,<xref rid="B127-toxins-17-00091" ref-type="bibr">127</xref>]. Other rare effects include dysphagia and speech difficulties resulting from unintended spread to the adjacent muscles, as well as transient facial nerve palsy causing asymmetry or weakness. These complications can be avoided with refined injection techniques and precise localization of the toxin [<xref rid="B62-toxins-17-00091" ref-type="bibr">62</xref>]. Systemic toxicity, while extremely rare, underscores the importance of adhering to safe dosing practices and immediate intervention in case of overdose [<xref rid="B119-toxins-17-00091" ref-type="bibr">119</xref>]. Long-term use of BoNT/A in masticatory muscles has raised concerns about mandibular bone thinning, particularly in animal studies. Several studies have examined the impact of BoNT/A injections on mandibular bone structure [<xref rid="B123-toxins-17-00091" ref-type="bibr">123</xref>,<xref rid="B124-toxins-17-00091" ref-type="bibr">124</xref>,<xref rid="B125-toxins-17-00091" ref-type="bibr">125</xref>,<xref rid="B126-toxins-17-00091" ref-type="bibr">126</xref>,<xref rid="B127-toxins-17-00091" ref-type="bibr">127</xref>]. Moussa et al. [<xref rid="B123-toxins-17-00091" ref-type="bibr">123</xref>] have recently reported, in a systematic review and meta-analysis, the adverse effects of BoNT/A injections on mandibular bone tissue. The authors reviewed both preclinical and clinical studies to assess the impact of BoNT/A dosage on bone density and mandibular structure. We recognize that the dose&#x02013;response relationship is a critical factor in interpreting the findings of both preclinical and clinical studies. The author found that in animal studies, higher doses of BoNT/A were employed relative to muscle mass compared to the doses used in human studies. Conversely, human studies typically used doses within the therapeutic range (e.g., 20&#x02013;50 units per side for masseter hypertrophy), which are less likely to result in significant bone changes. Therefore, the higher doses in animal models have demonstrated more pronounced effects on mandibular bone density and microarchitecture, while lower, therapeutic doses in humans appear to have minimal or no clinically significant impact. However, the authors concluded that while the preclinical evidence points to negative effects of BoNT/A on mandibular bone health, the clinical evidence remains insufficient to draw definitive conclusions [<xref rid="B123-toxins-17-00091" ref-type="bibr">123</xref>]. They recommend caution with prolonged or high-dose BoNT/A use in masticatory muscles and emphasize the need for further clinical research to assess the long-term impact of these treatments on mandibular bone structure. Hong et al. [<xref rid="B124-toxins-17-00091" ref-type="bibr">124</xref>] observed a reduction in cortical bone quality following BoNT/A injections, highlighting the potential for bone structure deterioration due to decreased mechanical loading. Research by Tsai et al. on rats [<xref rid="B125-toxins-17-00091" ref-type="bibr">125</xref>] indicated that BoNT/A injections into masticatory muscles led to reduced cortical bone thickness in specific mandibular regions, such as the angular process, due to muscle atrophy and subsequently decreased mechanical forces. Kahn et al. [<xref rid="B126-toxins-17-00091" ref-type="bibr">126</xref>] reported that BoNT/A-induced muscle atrophy resulted in decreased bone quality in the mandibular condyle and alveolar bones, emphasizing the relationship between muscle function and bone integrity. These studies collectively suggest that BoNT/A injections can lead to a reduction in mandibular bone quality, particularly in cortical thickness, due to the interruption of normal bone remodeling processes. The regions of interest commonly affected include the mandibular condyle, coronoid process, and angle/ramus, with significant changes observed within 3 to 12 months post-injection [<xref rid="B126-toxins-17-00091" ref-type="bibr">126</xref>]. Therefore, mandibular bone loss could be considered an adverse effect of BoNT/A&#x02019;s application on masticatory muscles; even though more studies are needed, the results extrapolated to humans [<xref rid="B102-toxins-17-00091" ref-type="bibr">102</xref>] highlight the need for caution in prolonged or high-dose treatments [<xref rid="B126-toxins-17-00091" ref-type="bibr">126</xref>]. Allergic reactions such as allergic dermatitis or antibody formation, although rare, have been described in a small percentage of patients, while systemic reactions of flu-like symptoms or generalized malaise are exceedingly rare [<xref rid="B127-toxins-17-00091" ref-type="bibr">127</xref>]. These reactions are usually mild and self-limiting [<xref rid="B127-toxins-17-00091" ref-type="bibr">127</xref>]. Genetic predispositions and immune variability among patients may further influence susceptibility to these events [<xref rid="B120-toxins-17-00091" ref-type="bibr">120</xref>]. Management strategies focus on using the lowest effective dose, extending intervals between treatments, and considering alternative formulations when antibody resistance is suspected [<xref rid="B120-toxins-17-00091" ref-type="bibr">120</xref>]. Huang et al. [<xref rid="B66-toxins-17-00091" ref-type="bibr">66</xref>] demonstrated that three-dimensional photography combined with ultrasound could track volume reduction more accurately, enabling better patient satisfaction and tailored treatments. The injection of botulinum toxin into the orofacial region can also be guided with the help of electromyography [<xref rid="B110-toxins-17-00091" ref-type="bibr">110</xref>,<xref rid="B126-toxins-17-00091" ref-type="bibr">126</xref>]. To reduce the incidence of rare complications associated with BoNT/A treatments, practitioners can employ several preventative strategies focusing on precision, technique, and patient-specific factors, including the use of ultrasound-guided injections.</p><p>To mitigate immune-mediated responses, it is crucial to minimize cumulative doses and extend the intervals between treatments. For patients who develop resistance due to neutralizing antibody formation, switching to alternative toxin formulations may restore efficacy [<xref rid="B121-toxins-17-00091" ref-type="bibr">121</xref>]. Finally, patient education cannot be overlooked. Informing patients about potential transient effects, such as mild chewing weakness or temporary facial asymmetry, prepares them for recovery. Advising rest post-treatment can further help reduce minor side effects like dizziness or headaches. With a combination of advanced guidance tools, careful injection planning, personalized treatment approaches, and patient education, clinicians can significantly reduce the risk of rare complications. These strategies ensure safer and more effective outcomes in botulinum toxin therapies [<xref rid="B69-toxins-17-00091" ref-type="bibr">69</xref>,<xref rid="B93-toxins-17-00091" ref-type="bibr">93</xref>,<xref rid="B118-toxins-17-00091" ref-type="bibr">118</xref>,<xref rid="B124-toxins-17-00091" ref-type="bibr">124</xref>,<xref rid="B127-toxins-17-00091" ref-type="bibr">127</xref>]. <xref rid="toxins-17-00091-t003" ref-type="table">Table 3</xref> depicts the risks and mitigation methods in detail.</p></sec></sec><sec id="sec9-toxins-17-00091"><title>9. Limitations of This Study</title><p>The present study has the main limitation of being a narrative review. Thus, this study&#x02019;s design did not allow us to provide evidence according to systematic research of the scientific literature, nor did it provide quantitative conclusions. Additionally, variability in the designs, sample sizes, and methodologies across the included studies is a limiting factor. Furthermore, the lack of randomized controlled trials comparing botulinum toxin protocols for masseter hypertrophy represents another limitation.</p></sec><sec sec-type="conclusions" id="sec10-toxins-17-00091"><title>10. Conclusions</title><p>In summary, BoNT/A injections in the masseter muscle are a valuable tool for both therapeutic and aesthetic purposes. The treatment of MMH with botulinum toxin requires a careful balance of dosage, technique, and frequency to achieve both functional and aesthetic improvements. While significant advancements have been made in refining protocols, the variability in each patient&#x02019;s anatomy and needs underscores the importance of individualized treatment planning. BoNT-A is effective and safe in the treatment of MMH and TMDs, offering significant benefits in terms of pain reduction, improvement in muscle and joint function, and aesthetic advantages, with effects lasting several months. While most side effects are mild and self-limiting, rare complications underscore the importance of precision, advanced techniques, and individualized treatment planning. By utilizing innovations like ultrasound-guided injections, clinicians can further enhance the safety and efficacy of these treatments. Continued research into the long-term effects of BoNT/A, particularly on mandibular bone health, is essential to ensure optimal patient outcomes. Future studies are needed to establish more definitive guidelines for optimal dosing, injection sites, and treatment intervals and to better understand the mechanisms underlying botulinum toxin&#x02019;s effects on muscle function.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, M.F., E.S. and A.d.S.; methodology, M.F. and A.d.S.; software, L.R.; investigation, M.F., E.S., L.R., D.C., L.L. and A.d.S.; data curation, U.G.L., L.L. and A.d.S.; writing&#x02014;original draft preparation, M.F., E.S., L.R. and D.C.; writing&#x02014;review and editing, U.G.L., L.L. and A.d.S.; visualization, K.M., V.T. and M.V.; supervision, U.G.L., L.L. and A.d.S. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>No new data were created or analyzed in this study. Data sharing is not applicable to this article.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>M.V. received consultancy honoraria from Ipsen, not related to this manuscript.</p></notes><ref-list><title>References</title><ref id="B1-toxins-17-00091"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Smyth</surname><given-names>A.G.</given-names></name>
</person-group><article-title>Botulinum toxin treatment of bilateral masseteric hypertrophy</article-title><source>Br. J. Oral Maxillofac. Surg.</source><year>1994</year><volume>32</volume><fpage>29</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/0266-4356(94)90169-4</pub-id><pub-id pub-id-type="pmid">8136335</pub-id>
</element-citation></ref><ref id="B2-toxins-17-00091"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gurney</surname><given-names>C.E.</given-names></name>
</person-group><article-title>Chronic bilateral benign hypertrophy of the masseter muscles</article-title><source>Am. J. Surg.</source><year>1947</year><volume>73</volume><fpage>137</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1016/0002-9610(47)90304-8</pub-id><pub-id pub-id-type="pmid">20279395</pub-id>
</element-citation></ref><ref id="B3-toxins-17-00091"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baek</surname><given-names>S.M.</given-names></name>
<name><surname>Kim</surname><given-names>S.S.</given-names></name>
<name><surname>Bindiger</surname><given-names>A.</given-names></name>
</person-group><article-title>The prominent mandibular angle: Preoperative management, operative technique, and results in 42 patients</article-title><source>Plast. Reconstr. Surg.</source><year>1989</year><volume>83</volume><fpage>272</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1097/00006534-198902000-00012</pub-id><pub-id pub-id-type="pmid">2911627</pub-id>
</element-citation></ref><ref id="B4-toxins-17-00091"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xie</surname><given-names>Q.</given-names></name>
<name><surname>Yang</surname><given-names>C.</given-names></name>
</person-group><article-title>Masticatory muscle hypertrophy: Etiology and management strategies</article-title><source>Oral Dis.</source><year>2018</year><volume>24</volume><fpage>13</fpage><lpage>20</lpage></element-citation></ref><ref id="B5-toxins-17-00091"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rispoli</surname><given-names>D.Z.</given-names></name>
<name><surname>Camargo</surname><given-names>P.M.</given-names></name>
<name><surname>Pires</surname><given-names>J.L.</given-names><suffix>Jr.</suffix></name>
<name><surname>Fonseca</surname><given-names>V.R.</given-names></name>
<name><surname>Mandelli</surname><given-names>K.K.</given-names></name>
<name><surname>Pereira</surname><given-names>M.A.C.</given-names></name>
</person-group><article-title>Benign masseter muscle hypertrophy</article-title><source>Braz. J. Otorhinolaryngol.</source><year>2008</year><volume>74</volume><fpage>790</fpage><lpage>793</lpage><pub-id pub-id-type="doi">10.1016/S1808-8694(15)31393-8</pub-id><pub-id pub-id-type="pmid">19082365</pub-id>
</element-citation></ref><ref id="B6-toxins-17-00091"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fedorowicz</surname><given-names>Z.</given-names></name>
<name><surname>van Zuuren</surname><given-names>E.J.</given-names></name>
<name><surname>Schoones</surname><given-names>J.</given-names></name>
</person-group><article-title>Botulinum toxin for masseter hypertrophy</article-title><source>Cochrane Database Syst. Rev.</source><year>2013</year><volume>2013</volume><fpage>CD007510</fpage><pub-id pub-id-type="doi">10.1002/14651858.CD007510.pub3</pub-id><pub-id pub-id-type="pmid">24018587</pub-id>
</element-citation></ref><ref id="B7-toxins-17-00091"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Singh</surname><given-names>S.</given-names></name>
<name><surname>Shivamurthy</surname><given-names>D.M.</given-names></name>
<name><surname>Agrawal</surname><given-names>G.</given-names></name>
<name><surname>Varghese</surname><given-names>D.</given-names></name>
</person-group><article-title>Surgical management of masseteric hypertrophy and mandibular retrognathism</article-title><source>Natl. J. Maxillofac. Surg.</source><year>2011</year><volume>2</volume><fpage>96</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">22442621</pub-id>
</element-citation></ref><ref id="B8-toxins-17-00091"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Srivastava</surname><given-names>S.</given-names></name>
<name><surname>Kharbanda</surname><given-names>S.</given-names></name>
<name><surname>Pal</surname><given-names>U.S.</given-names></name>
<name><surname>Shah</surname><given-names>V.</given-names></name>
</person-group><article-title>Applications of botulinum toxin in dentistry: A comprehensive review</article-title><source>Natl. J. Maxillofac. Surg.</source><year>2015</year><volume>6</volume><fpage>152</fpage><lpage>159</lpage><pub-id pub-id-type="pmid">27390488</pub-id>
</element-citation></ref><ref id="B9-toxins-17-00091"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ferrillo</surname><given-names>M.</given-names></name>
<name><surname>Gallo</surname><given-names>V.</given-names></name>
<name><surname>Lippi</surname><given-names>L.</given-names></name>
<name><surname>Bruni</surname><given-names>A.</given-names></name>
<name><surname>Montrella</surname><given-names>R.</given-names></name>
<name><surname>Curci</surname><given-names>C.</given-names></name>
<name><surname>Calafiore</surname><given-names>D.</given-names></name>
<name><surname>Invernizzi</surname><given-names>M.</given-names></name>
<name><surname>Migliario</surname><given-names>M.</given-names></name>
<name><surname>de Sire</surname><given-names>A.</given-names></name>
</person-group><article-title>The 50 most-cited articles on temporomandibular disorders: A bibliometric analysis</article-title><source>J. Back Musculoskelet. Rehabil.</source><year>2023</year><volume>36</volume><fpage>279</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.3233/BMR-220152</pub-id><pub-id pub-id-type="pmid">36189581</pub-id>
</element-citation></ref><ref id="B10-toxins-17-00091"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ferrillo</surname><given-names>M.</given-names></name>
<name><surname>Migliario</surname><given-names>M.</given-names></name>
<name><surname>Marotta</surname><given-names>N.</given-names></name>
<name><surname>Fortunato</surname><given-names>F.</given-names></name>
<name><surname>Bindi</surname><given-names>M.</given-names></name>
<name><surname>Pezzotti</surname><given-names>F.</given-names></name>
<name><surname>Ammendolia</surname><given-names>A.</given-names></name>
<name><surname>Giudice</surname><given-names>A.</given-names></name>
<name><surname>Bonda</surname><given-names>P.L.F.</given-names></name>
<name><surname>de Sire</surname><given-names>A.</given-names></name>
</person-group><article-title>Temporomandibular disorders and neck pain in primary headache patients: A retrospective machine learning study</article-title><source>Acta Odontol. Scand.</source><year>2023</year><volume>81</volume><fpage>151</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1080/00016357.2022.2105945</pub-id><pub-id pub-id-type="pmid">35906722</pub-id>
</element-citation></ref><ref id="B11-toxins-17-00091"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ferrillo</surname><given-names>M.</given-names></name>
<name><surname>Marotta</surname><given-names>N.</given-names></name>
<name><surname>Giudice</surname><given-names>A.</given-names></name>
<name><surname>Calafiore</surname><given-names>D.</given-names></name>
<name><surname>Curci</surname><given-names>C.</given-names></name>
<name><surname>Fortunato</surname><given-names>L.</given-names></name>
<name><surname>Ammendolia</surname><given-names>A.</given-names></name>
<name><surname>de Sire</surname><given-names>A.</given-names></name>
</person-group><article-title>Effects of Occlusal Splints on Spinal Posture in Patients with Temporomandibular Disorders: A Systematic Review</article-title><source>Healthcare</source><year>2022</year><volume>10</volume><elocation-id>739</elocation-id><pub-id pub-id-type="doi">10.3390/healthcare10040739</pub-id><pub-id pub-id-type="pmid">35455916</pub-id>
</element-citation></ref><ref id="B12-toxins-17-00091"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guarda-Nardini</surname><given-names>L.</given-names></name>
<name><surname>Piccotti</surname><given-names>F.</given-names></name>
<name><surname>Mogno</surname><given-names>G.</given-names></name>
<name><surname>Favero</surname><given-names>L.</given-names></name>
<name><surname>Manfredini</surname><given-names>D.</given-names></name>
</person-group><article-title>Age-related differences in temporomandibular disorder diagnoses</article-title><source>Cranio</source><year>2012</year><volume>30</volume><fpage>103</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1179/crn.2012.015</pub-id><pub-id pub-id-type="pmid">22606853</pub-id>
</element-citation></ref><ref id="B13-toxins-17-00091"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Deregibus</surname><given-names>A.</given-names></name>
<name><surname>Ferrillo</surname><given-names>M.</given-names></name>
<name><surname>Grazia Piancino</surname><given-names>M.</given-names></name>
<name><surname>Chiara Domini</surname><given-names>M.</given-names></name>
<name><surname>de Sire</surname><given-names>A.</given-names></name>
<name><surname>Castroflorio</surname><given-names>T.</given-names></name>
</person-group><article-title>Are occlusal splints effective in reducing myofascial pain in patients with muscle-related temporomandibular disorders? A randomized-controlled trial</article-title><source>Turk. J. Phys. Med. Rehabil.</source><year>2021</year><volume>67</volume><fpage>32</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.5606/tftrd.2021.6615</pub-id><pub-id pub-id-type="pmid">33948541</pub-id>
</element-citation></ref><ref id="B14-toxins-17-00091"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moore</surname><given-names>A.P.</given-names></name>
<name><surname>Wood</surname><given-names>G.D.</given-names></name>
</person-group><article-title>The medical management of masseteric hypertrophy with botulinum toxin type A</article-title><source>Br. J. Oral Maxillofac. Surg.</source><year>1994</year><volume>32</volume><fpage>26</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/0266-4356(94)90168-6</pub-id><pub-id pub-id-type="pmid">8136334</pub-id>
</element-citation></ref><ref id="B15-toxins-17-00091"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lippi</surname><given-names>L.</given-names></name>
<name><surname>Ferrillo</surname><given-names>M.</given-names></name>
<name><surname>Losco</surname><given-names>L.</given-names></name>
<name><surname>Folli</surname><given-names>A.</given-names></name>
<name><surname>Marcasciano</surname><given-names>M.</given-names></name>
<name><surname>Curci</surname><given-names>C.</given-names></name>
<name><surname>Moalli</surname><given-names>S.</given-names></name>
<name><surname>Ammendolia</surname><given-names>A.</given-names></name>
<name><surname>de Sire</surname><given-names>A.</given-names></name>
<name><surname>Invernizzi</surname><given-names>M.</given-names></name>
</person-group><article-title>Aesthetic Rehabilitation Medicine: Enhancing Wellbeing beyond Functional Recovery</article-title><source>Medicina</source><year>2024</year><volume>60</volume><elocation-id>603</elocation-id><pub-id pub-id-type="doi">10.3390/medicina60040603</pub-id><pub-id pub-id-type="pmid">38674249</pub-id>
</element-citation></ref><ref id="B16-toxins-17-00091"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bayrak</surname><given-names>N.B.</given-names></name>
<name><surname>Zeybek</surname><given-names>M.</given-names></name>
<name><surname>Sanlioglu</surname><given-names>I.</given-names></name>
<name><surname>Dolanmaz</surname><given-names>D.</given-names></name>
</person-group><article-title>Assessment of changes in masseter muscle by three-dimensional close-range photogrammetry after Botulinum toxin type-A injection: A case report with review of literature</article-title><source>J. Pak. Med. Assoc.</source><year>2019</year><volume>69</volume><fpage>418</fpage><lpage>422</lpage><pub-id pub-id-type="pmid">30890839</pub-id>
</element-citation></ref><ref id="B17-toxins-17-00091"><label>17.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Khawaja</surname><given-names>S.T.</given-names></name>
</person-group><article-title>A Systematic Review: The Use of Botulinum Toxin a for the Treatment of Masseter Hypertrophy and Masticatory Myofascial Pain Associated with Bruxism</article-title><source>Master&#x02019;s Thesis</source><publisher-name>Boston University</publisher-name><publisher-loc>Boston, MA, USA</publisher-loc><year>2024</year></element-citation></ref><ref id="B18-toxins-17-00091"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chiodo</surname><given-names>M.V.</given-names></name>
<name><surname>Lisiecki</surname><given-names>J.L.</given-names></name>
<name><surname>Rohrich</surname><given-names>R.J.</given-names></name>
</person-group><article-title>Neuromodulator Finesse for Masseter Hypertrophy and Bruxism</article-title><source>Plast. Reconstr. Surg.</source><year>2024</year><volume>153</volume><fpage>726e</fpage><lpage>729e</lpage></element-citation></ref><ref id="B19-toxins-17-00091"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Almukhtar</surname><given-names>R.M.</given-names></name>
<name><surname>Fabi</surname><given-names>S.G.</given-names></name>
</person-group><article-title>The Masseter Muscle and Its Role in Facial Contouring, Aging, and Quality of Life: A Literature Review</article-title><source>Plast. Reconstr. Surg.</source><year>2019</year><volume>143</volume><fpage>39e</fpage><lpage>48e</lpage><pub-id pub-id-type="doi">10.1097/PRS.0000000000005083</pub-id><pub-id pub-id-type="pmid">30589774</pub-id>
</element-citation></ref><ref id="B20-toxins-17-00091"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>Z.</given-names></name>
<name><surname>Chi</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>C.</given-names></name>
<name><surname>Jin</surname><given-names>L.</given-names></name>
<name><surname>Huang</surname><given-names>J.</given-names></name>
<name><surname>Long</surname><given-names>X.</given-names></name>
<name><surname>Yu</surname><given-names>N.</given-names></name>
</person-group><article-title>A Comprehensive Ultrasound Evaluation Approach of Lower Facial Structure Before Masseter Muscle Botulinum Toxin Injection</article-title><source>Aesthet. Surg. J.</source><year>2023</year><volume>43</volume><fpage>NP283</fpage><lpage>NP292</lpage><pub-id pub-id-type="doi">10.1093/asj/sjac336</pub-id><pub-id pub-id-type="pmid">36527687</pub-id>
</element-citation></ref><ref id="B21-toxins-17-00091"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Graziano</surname><given-names>P.</given-names></name>
<name><surname>Orabona</surname><given-names>G.D.</given-names></name>
<name><surname>Astarita</surname><given-names>F.</given-names></name>
<name><surname>Ponzo</surname><given-names>L.M.</given-names></name>
<name><surname>Nunziata</surname><given-names>R.</given-names></name>
<name><surname>Salzano</surname><given-names>G.</given-names></name>
<name><surname>Maglitto</surname><given-names>F.</given-names></name>
<name><surname>Solari</surname><given-names>D.</given-names></name>
<name><surname>Santella</surname><given-names>A.</given-names></name>
<name><surname>Cappabianca</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Bilateral hypertrophy of masseteric and temporalis muscles, our fifteen patients and review of literature</article-title><source>Eur. Rev. Med. Pharmacol. Sci.</source><year>2016</year><volume>20</volume><fpage>7</fpage><lpage>11</lpage></element-citation></ref><ref id="B22-toxins-17-00091"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guruprasad</surname><given-names>R.</given-names></name>
<name><surname>Rishi</surname><given-names>S.</given-names></name>
<name><surname>Nair</surname><given-names>P.P.</given-names></name>
<name><surname>Thomas</surname><given-names>S.</given-names></name>
</person-group><article-title>Masseter and medial pterygoid muscle hypertrophy</article-title><source>BMJ Case Rep.</source><year>2011</year><volume>2011</volume><fpage>bcr0720114557</fpage></element-citation></ref><ref id="B23-toxins-17-00091"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fyfe</surname><given-names>E.C.</given-names></name>
<name><surname>Kabala</surname><given-names>J.</given-names></name>
<name><surname>Guest</surname><given-names>P.G.</given-names></name>
</person-group><article-title>Magnetic resonance imaging in the diagnosis of asymmetrical bilateral masseteric hypertrophy</article-title><source>Dentomaxillofac. Radiol.</source><year>1999</year><volume>28</volume><fpage>52</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1038/sj.dmfr.4600394</pub-id><pub-id pub-id-type="pmid">10202480</pub-id>
</element-citation></ref><ref id="B24-toxins-17-00091"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Boltshauser</surname><given-names>E.</given-names></name>
</person-group><article-title>Hypertrophy of temporalis muscles due to chewing gum &#x0201c;abuse&#x0201d;</article-title><source>J. Child. Neurol.</source><year>1996</year><volume>11</volume><fpage>210</fpage><pub-id pub-id-type="doi">10.1177/088307389601100309</pub-id><pub-id pub-id-type="pmid">8734024</pub-id>
</element-citation></ref><ref id="B25-toxins-17-00091"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Olchowy</surname><given-names>C.</given-names></name>
<name><surname>Grzech-Le&#x0015b;niak</surname><given-names>K.</given-names></name>
<name><surname>Hadzik</surname><given-names>J.</given-names></name>
<name><surname>Olchowy</surname><given-names>A.</given-names></name>
<name><surname>&#x00141;asecki</surname><given-names>M.</given-names></name>
</person-group><article-title>Monitoring of Changes in Masticatory Muscle Stiffness after Gum Chewing Using Shear Wave Elastography</article-title><source>J. Clin. Med.</source><year>2021</year><volume>10</volume><elocation-id>2480</elocation-id><pub-id pub-id-type="doi">10.3390/jcm10112480</pub-id><pub-id pub-id-type="pmid">34205052</pub-id>
</element-citation></ref><ref id="B26-toxins-17-00091"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Park</surname><given-names>Y.J.</given-names></name>
<name><surname>Jo</surname><given-names>Y.W.</given-names></name>
<name><surname>Bang</surname><given-names>S.I.</given-names></name>
<name><surname>Kim</surname><given-names>H.J.</given-names></name>
<name><surname>Lim</surname><given-names>S.Y.</given-names></name>
<name><surname>Mun</surname><given-names>G.H.</given-names></name>
<name><surname>Hyon</surname><given-names>W.S.</given-names></name>
<name><surname>Oh</surname><given-names>K.S.</given-names></name>
</person-group><article-title>Radiofrequency volumetric reduction for masseteric hypertrophy</article-title><source>Aesthet. Plast. Surg.</source><year>2007</year><volume>31</volume><fpage>42</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1007/s00266-006-0151-3</pub-id><pub-id pub-id-type="pmid">17235460</pub-id>
</element-citation></ref><ref id="B27-toxins-17-00091"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kebede</surname><given-names>B.</given-names></name>
<name><surname>Megersa</surname><given-names>S.</given-names></name>
</person-group><article-title>Idiopathic masseter muscle hypertrophy</article-title><source>Ethiop. J. Health Sci.</source><year>2011</year><volume>21</volume><fpage>209</fpage><lpage>212</lpage><pub-id pub-id-type="pmid">22435002</pub-id>
</element-citation></ref><ref id="B28-toxins-17-00091"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nakata</surname><given-names>M.</given-names></name>
</person-group><article-title>Masticatory function and its effects on general health</article-title><source>Int. Dent. J.</source><year>1998</year><volume>48</volume><fpage>540</fpage><lpage>548</lpage><comment>Correction in <italic toggle="yes">Int. Dent. J.</italic>
<bold>1999</bold>, <italic toggle="yes">49</italic>, 3</comment><pub-id pub-id-type="doi">10.1111/j.1875-595X.1998.tb00489.x</pub-id><pub-id pub-id-type="pmid">9881286</pub-id>
</element-citation></ref><ref id="B29-toxins-17-00091"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kumar</surname><given-names>A.</given-names></name>
<name><surname>Almotairy</surname><given-names>N.</given-names></name>
<name><surname>Merzo</surname><given-names>J.J.</given-names></name>
<name><surname>Wendin</surname><given-names>K.</given-names></name>
<name><surname>Rothenberg</surname><given-names>E.</given-names></name>
<name><surname>Grigoriadis</surname><given-names>A.</given-names></name>
<name><surname>Sandborgh-Englund</surname><given-names>G.</given-names></name>
<name><surname>Trulsson</surname><given-names>M.</given-names></name>
</person-group><article-title>Chewing and its influence on swallowing, gastrointestinal and nutrition-related factors: A systematic review</article-title><source>Crit. Rev. Food Sci. Nutr.</source><year>2023</year><volume>63</volume><fpage>11987</fpage><lpage>12017</lpage><pub-id pub-id-type="doi">10.1080/10408398.2022.2098245</pub-id><pub-id pub-id-type="pmid">35837677</pub-id>
</element-citation></ref><ref id="B30-toxins-17-00091"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sannomya</surname><given-names>E.K.</given-names></name>
<name><surname>Gon&#x000e7;alves</surname><given-names>M.</given-names></name>
<name><surname>Cavalcanti</surname><given-names>M.P.</given-names></name>
</person-group><article-title>Masseter muscle hypertrophy: Case report</article-title><source>Braz. Dent. J.</source><year>2006</year><volume>17</volume><fpage>347</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1590/S0103-64402006000400015</pub-id><pub-id pub-id-type="pmid">17262151</pub-id>
</element-citation></ref><ref id="B31-toxins-17-00091"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nikolis</surname><given-names>A.</given-names></name>
<name><surname>Enright</surname><given-names>K.M.</given-names></name>
<name><surname>Rudolph</surname><given-names>C.</given-names></name>
<name><surname>Cotofana</surname><given-names>S.</given-names></name>
</person-group><article-title>Temporal volume increase after reduction of masseteric hypertrophy utilizing incobotulinumtoxin type A</article-title><source>J. Cosmet. Dermatol.</source><year>2020</year><volume>19</volume><fpage>1294</fpage><lpage>1300</lpage><pub-id pub-id-type="doi">10.1111/jocd.13434</pub-id><pub-id pub-id-type="pmid">32338450</pub-id>
</element-citation></ref><ref id="B32-toxins-17-00091"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Satoh</surname><given-names>K.</given-names></name>
<name><surname>Yamaguchi</surname><given-names>T.</given-names></name>
<name><surname>Komatsu</surname><given-names>K.</given-names></name>
<name><surname>Inoue</surname><given-names>N.</given-names></name>
<name><surname>Minowa</surname><given-names>K.</given-names></name>
<name><surname>Kanayama</surname><given-names>T.</given-names></name>
<name><surname>Yoshida</surname><given-names>S.</given-names></name>
<name><surname>Ohata</surname><given-names>N.</given-names></name>
</person-group><article-title>Analyses of muscular activity, energy metabolism, and muscle fiber type composition in a patient with bilateral masseteric hypertrophy</article-title><source>Cranio</source><year>2001</year><volume>19</volume><fpage>294</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1080/08869634.2001.11746181</pub-id><pub-id pub-id-type="pmid">11725854</pub-id>
</element-citation></ref><ref id="B33-toxins-17-00091"><label>33.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Okeson</surname><given-names>J.P.</given-names></name>
</person-group><source>Management of Temporomandibular Disorders and Occlusion</source><edition>8th ed.</edition><publisher-name>Elsevier Health Sciences</publisher-name><publisher-loc>St. Louis, MO, USA</publisher-loc><year>2020</year></element-citation></ref><ref id="B34-toxins-17-00091"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>St&#x000e5;l</surname><given-names>P.</given-names></name>
<name><surname>Erikssonm</surname><given-names>P.O.</given-names></name>
<name><surname>Schiaffino</surname><given-names>S.</given-names></name>
<name><surname>Butler-Browne</surname><given-names>G.S.</given-names></name>
<name><surname>Thornell</surname><given-names>L.E.</given-names></name>
</person-group><article-title>Differences in myosin composition between human oro-facial, masticatory and limb muscles: Enzyme-, immunohisto- and biochemical studies</article-title><source>J. Muscle Res. Cell Motil.</source><year>1994</year><volume>15</volume><fpage>517</fpage><lpage>534</lpage><pub-id pub-id-type="doi">10.1007/BF00121158</pub-id><pub-id pub-id-type="pmid">7860700</pub-id>
</element-citation></ref><ref id="B35-toxins-17-00091"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Korfage</surname><given-names>J.A.</given-names></name>
<name><surname>Koolstra</surname><given-names>J.H.</given-names></name>
<name><surname>Langenbach</surname><given-names>G.E.</given-names></name>
<name><surname>van Eijden</surname><given-names>T.M.</given-names></name>
</person-group><article-title>Fiber-type composition of the human jaw muscles&#x02014;(Part 1) origin and functional significance of fiber-type diversity</article-title><source>J. Dent. Res.</source><year>2005</year><volume>84</volume><fpage>774</fpage><lpage>783</lpage><pub-id pub-id-type="doi">10.1177/154405910508400901</pub-id><pub-id pub-id-type="pmid">16109984</pub-id>
</element-citation></ref><ref id="B36-toxins-17-00091"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kato</surname><given-names>Y.</given-names></name>
<name><surname>Hoshino</surname><given-names>T.</given-names></name>
<name><surname>Ogawa</surname><given-names>Y.</given-names></name>
<name><surname>Sugahara</surname><given-names>K.</given-names></name>
<name><surname>Katakura</surname><given-names>A.</given-names></name>
</person-group><article-title>Aging-Related Metabolome Analysis of the Masseter Muscle in Senescence-Accelerated Mouse-Prone 8</article-title><source>Int. J. Mol. Sci.</source><year>2024</year><volume>25</volume><elocation-id>9684</elocation-id><pub-id pub-id-type="doi">10.3390/ijms25179684</pub-id><pub-id pub-id-type="pmid">39273631</pub-id>
</element-citation></ref><ref id="B37-toxins-17-00091"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Eriksson</surname><given-names>P.O.</given-names></name>
<name><surname>Thornell</surname><given-names>L.E.</given-names></name>
</person-group><article-title>Histochemical and morphological muscle-fibre characteristics of the human masseter, the medial pterygoid and the temporal muscles</article-title><source>Arch. Oral Biol.</source><year>1983</year><volume>28</volume><fpage>781</fpage><lpage>795</lpage><pub-id pub-id-type="doi">10.1016/0003-9969(83)90034-1</pub-id><pub-id pub-id-type="pmid">6227313</pub-id>
</element-citation></ref><ref id="B38-toxins-17-00091"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Niszezak</surname><given-names>C.M.</given-names></name>
<name><surname>Sonza</surname><given-names>A.</given-names></name>
<name><surname>Garrett</surname><given-names>A.</given-names></name>
<name><surname>Santos</surname><given-names>G.M.</given-names></name>
</person-group><article-title>Muscle oxygenation and pain in different types of temporomandibular disorders</article-title><source>Clin. Oral Investig.</source><year>2024</year><volume>28</volume><fpage>410</fpage><pub-id pub-id-type="doi">10.1007/s00784-024-05806-z</pub-id></element-citation></ref><ref id="B39-toxins-17-00091"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>Y.</given-names></name>
<name><surname>Zhu</surname><given-names>J.</given-names></name>
<name><surname>Yin</surname><given-names>D.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
</person-group><article-title>Improved stomatognathic model for highly realistic finite element analysis of temporomandibular joint biomechanics</article-title><source>J. Mech. Behav. Biomed. Mater.</source><year>2024</year><volume>160</volume><elocation-id>106780</elocation-id><pub-id pub-id-type="doi">10.1016/j.jmbbm.2024.106780</pub-id><pub-id pub-id-type="pmid">39423565</pub-id>
</element-citation></ref><ref id="B40-toxins-17-00091"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baricich</surname><given-names>A.</given-names></name>
<name><surname>Picelli</surname><given-names>A.</given-names></name>
<name><surname>Santamato</surname><given-names>A.</given-names></name>
<name><surname>Carda</surname><given-names>S.</given-names></name>
<name><surname>de Sire</surname><given-names>A.</given-names></name>
<name><surname>Smania</surname><given-names>N.</given-names></name>
<name><surname>Cisari</surname><given-names>C.</given-names></name>
<name><surname>Invernizzi</surname><given-names>M.</given-names></name>
</person-group><article-title>Safety Profile of High-Dose Botulinum Toxin Type A in Post-Stroke Spasticity Treatment</article-title><source>Clin. Drug Investig.</source><year>2018</year><volume>38</volume><fpage>991</fpage><lpage>1000</lpage><pub-id pub-id-type="doi">10.1007/s40261-018-0701-x</pub-id><pub-id pub-id-type="pmid">30209743</pub-id>
</element-citation></ref><ref id="B41-toxins-17-00091"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Neumeyer</surname><given-names>T.</given-names></name>
<name><surname>Schiffler</surname><given-names>B.</given-names></name>
<name><surname>Maier</surname><given-names>E.</given-names></name>
<name><surname>Lang</surname><given-names>A.E.</given-names></name>
<name><surname>Aktories</surname><given-names>K.</given-names></name>
<name><surname>Benz</surname><given-names>R.</given-names></name>
</person-group><article-title>Clostridium botulinum C2 toxin. Identification of the binding site for chloroquine and related compounds and influence of the binding site on properties of the C2II channel</article-title><source>J. Biol. Chem.</source><year>2008</year><volume>283</volume><fpage>3904</fpage><lpage>3914</lpage><pub-id pub-id-type="doi">10.1074/jbc.M709807200</pub-id><pub-id pub-id-type="pmid">18077455</pub-id>
</element-citation></ref><ref id="B42-toxins-17-00091"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Raciti</surname><given-names>L.</given-names></name>
<name><surname>Raciti</surname><given-names>G.</given-names></name>
<name><surname>Ammendolia</surname><given-names>A.</given-names></name>
<name><surname>de Sire</surname><given-names>A.</given-names></name>
<name><surname>Onesta</surname><given-names>M.P.</given-names></name>
<name><surname>Calabr&#x000f2;</surname><given-names>R.S.</given-names></name>
</person-group><article-title>Improving Spasticity by Using Botulin Toxin: An Overview Focusing on Combined Approaches</article-title><source>Brain Sci.</source><year>2024</year><volume>14</volume><elocation-id>631</elocation-id><pub-id pub-id-type="doi">10.3390/brainsci14070631</pub-id><pub-id pub-id-type="pmid">39061372</pub-id>
</element-citation></ref><ref id="B43-toxins-17-00091"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tam</surname><given-names>E.</given-names></name>
<name><surname>Choo</surname><given-names>J.P.S.</given-names></name>
<name><surname>Rao</surname><given-names>P.</given-names></name>
<name><surname>Webb</surname><given-names>W.R.</given-names></name>
<name><surname>Carruthers</surname><given-names>J.D.A.</given-names></name>
<name><surname>Rahman</surname><given-names>E.</given-names></name>
</person-group><article-title>A Systematic Review on the Effectiveness and Safety of Combining Biostimulators with Botulinum Toxin, Dermal Fillers, and Energy-Based Devices</article-title><source>Aesthet. Plast. Surg.</source><year>2024</year><pub-id pub-id-type="doi">10.1007/s00266-024-04627-5</pub-id></element-citation></ref><ref id="B44-toxins-17-00091"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dressler</surname><given-names>D.</given-names></name>
<name><surname>Benecke</surname><given-names>R.</given-names></name>
</person-group><article-title>Pharmacology of therapeutic botulinum toxin preparations</article-title><source>Disabil. Rehabil.</source><year>2007</year><volume>29</volume><fpage>1761</fpage><lpage>1768</lpage><pub-id pub-id-type="doi">10.1080/09638280701568296</pub-id><pub-id pub-id-type="pmid">18033601</pub-id>
</element-citation></ref><ref id="B45-toxins-17-00091"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hambleton</surname><given-names>P.</given-names></name>
</person-group><article-title>Clostridium botulinum toxins: A general review of involvement in disease, structure, mode of action and preparation for clinical use</article-title><source>J. Neurol.</source><year>1992</year><volume>239</volume><fpage>16</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1007/BF00839205</pub-id><pub-id pub-id-type="pmid">1311751</pub-id>
</element-citation></ref><ref id="B46-toxins-17-00091"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baricich</surname><given-names>A.</given-names></name>
<name><surname>Picelli</surname><given-names>A.</given-names></name>
<name><surname>Carda</surname><given-names>S.</given-names></name>
<name><surname>Smania</surname><given-names>N.</given-names></name>
<name><surname>Cisari</surname><given-names>C.</given-names></name>
<name><surname>Santamato</surname><given-names>A.</given-names></name>
<name><surname>de Sire</surname><given-names>A.</given-names></name>
<name><surname>Invernizzi</surname><given-names>M.</given-names></name>
</person-group><article-title>Electrical stimulation of antagonist muscles after botulinum toxin type A for post-stroke spastic equinus foot. A randomized single-blind pilot study</article-title><source>Ann. Phys. Rehabil. Med.</source><year>2019</year><volume>62</volume><fpage>214</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1016/j.rehab.2019.06.002</pub-id><pub-id pub-id-type="pmid">31228593</pub-id>
</element-citation></ref><ref id="B47-toxins-17-00091"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lippi</surname><given-names>L.</given-names></name>
<name><surname>de Sire</surname><given-names>A.</given-names></name>
<name><surname>Folli</surname><given-names>A.</given-names></name>
<name><surname>D&#x02019;abrosca</surname><given-names>F.</given-names></name>
<name><surname>Grana</surname><given-names>E.</given-names></name>
<name><surname>Baricich</surname><given-names>A.</given-names></name>
<name><surname>Carda</surname><given-names>S.</given-names></name>
<name><surname>Invernizzi</surname><given-names>M.</given-names></name>
</person-group><article-title>Multidimensional Effectiveness of Botulinum Toxin in Neuropathic Pain: A Systematic Review of Randomized Clinical Trials</article-title><source>Toxins</source><year>2022</year><volume>14</volume><elocation-id>308</elocation-id><pub-id pub-id-type="doi">10.3390/toxins14050308</pub-id><pub-id pub-id-type="pmid">35622555</pub-id>
</element-citation></ref><ref id="B48-toxins-17-00091"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Burstein</surname><given-names>R.</given-names></name>
<name><surname>Blumenfeld</surname><given-names>A.M.</given-names></name>
<name><surname>Silberstein</surname><given-names>S.D.</given-names></name>
<name><surname>Manack Adams</surname><given-names>A.</given-names></name>
<name><surname>Brin</surname><given-names>M.F.</given-names></name>
</person-group><article-title>Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review</article-title><source>Headache</source><year>2020</year><volume>60</volume><fpage>1259</fpage><lpage>1272</lpage><pub-id pub-id-type="doi">10.1111/head.13849</pub-id><pub-id pub-id-type="pmid">32602955</pub-id>
</element-citation></ref><ref id="B49-toxins-17-00091"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ho</surname><given-names>T.W.</given-names></name>
<name><surname>Edvinsson</surname><given-names>L.</given-names></name>
<name><surname>Goadsby</surname><given-names>P.J.</given-names></name>
</person-group><article-title>CGRP and its receptors provide new insights into migraine pathophysiology</article-title><source>Nat. Rev. Neurol.</source><year>2010</year><volume>6</volume><fpage>573</fpage><lpage>582</lpage><pub-id pub-id-type="doi">10.1038/nrneurol.2010.127</pub-id><pub-id pub-id-type="pmid">20820195</pub-id>
</element-citation></ref><ref id="B50-toxins-17-00091"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ramachandran</surname><given-names>R.</given-names></name>
<name><surname>Lam</surname><given-names>C.</given-names></name>
<name><surname>Yaksh</surname><given-names>T.L.</given-names></name>
</person-group><article-title>Botulinum toxin in migraine: Role of transport in trigemino-somatic and trigemino-vascular afferents</article-title><source>Neurobiol. Dis.</source><year>2015</year><volume>79</volume><fpage>111</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2015.04.011</pub-id><pub-id pub-id-type="pmid">25958249</pub-id>
</element-citation></ref><ref id="B51-toxins-17-00091"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cernuda-Moroll&#x000f3;n</surname><given-names>E.</given-names></name>
<name><surname>Ram&#x000f3;n</surname><given-names>C.</given-names></name>
<name><surname>Mart&#x000ed;nez-Camblor</surname><given-names>P.</given-names></name>
<name><surname>Serrano-Pertierra</surname><given-names>E.</given-names></name>
<name><surname>Larrosa</surname><given-names>D.</given-names></name>
<name><surname>Pascual</surname><given-names>J.</given-names></name>
</person-group><article-title>OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine</article-title><source>Pain</source><year>2015</year><volume>156</volume><fpage>820</fpage><lpage>824</lpage><pub-id pub-id-type="doi">10.1097/j.pain.0000000000000119</pub-id><pub-id pub-id-type="pmid">25735000</pub-id>
</element-citation></ref><ref id="B52-toxins-17-00091"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ceruti</surname><given-names>S.</given-names></name>
<name><surname>Villa</surname><given-names>G.</given-names></name>
<name><surname>Fumagalli</surname><given-names>M.</given-names></name>
<name><surname>Colombo</surname><given-names>L.</given-names></name>
<name><surname>Magni</surname><given-names>G.</given-names></name>
<name><surname>Zanardelli</surname><given-names>M.</given-names></name>
<name><surname>Fabbretti</surname><given-names>E.</given-names></name>
<name><surname>Verderio</surname><given-names>C.</given-names></name>
<name><surname>van den Maagdenberg</surname><given-names>A.M.</given-names></name>
<name><surname>Nistri</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Calcitonin gene-related peptide-mediated enhancement of purinergic neuron/glia communication by the algogenic factor bradykinin in mouse trigeminal ganglia from wild-type and R192Q Cav2.1 Knock-in mice: Implications for basic mechanisms of migraine pain</article-title><source>J. Neurosci.</source><year>2011</year><volume>31</volume><fpage>3638</fpage><lpage>3649</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.6440-10.2011</pub-id><pub-id pub-id-type="pmid">21389219</pub-id>
</element-citation></ref><ref id="B53-toxins-17-00091"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lu</surname><given-names>Y.</given-names></name>
<name><surname>Jiang</surname><given-names>Q.</given-names></name>
<name><surname>Yu</surname><given-names>L.</given-names></name>
<name><surname>Lu</surname><given-names>Z.-Y.</given-names></name>
<name><surname>Meng</surname><given-names>S.-P.</given-names></name>
<name><surname>Su</surname><given-names>D.</given-names></name>
<name><surname>Burnstock</surname><given-names>G.</given-names></name>
<name><surname>Ma</surname><given-names>B.</given-names></name>
</person-group><article-title>17&#x003b2;-estradiol rapidly attenuates P2X3 receptor-mediated peripheral pain signal transduction via ER&#x003b1; and GPR30</article-title><source>Endocrinology</source><year>2013</year><volume>154</volume><fpage>2421</fpage><lpage>2433</lpage><pub-id pub-id-type="doi">10.1210/en.2012-2119</pub-id><pub-id pub-id-type="pmid">23610132</pub-id>
</element-citation></ref><ref id="B54-toxins-17-00091"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Strassman</surname><given-names>A.M.</given-names></name>
<name><surname>Novack</surname><given-names>V.</given-names></name>
<name><surname>Brin</surname><given-names>M.F.</given-names></name>
<name><surname>Burstein</surname><given-names>R.</given-names></name>
</person-group><article-title>Extracranial injections of botulinum neurotoxin type A inhibit intracranial meningeal nociceptors&#x02019; responses to stimulation of TRPV1 and TRPA1 channels: Are we getting closer to solving this puzzle?</article-title><source>Cephalalgia</source><year>2016</year><volume>36</volume><fpage>875</fpage><lpage>886</lpage><pub-id pub-id-type="doi">10.1177/0333102416636843</pub-id><pub-id pub-id-type="pmid">26984967</pub-id>
</element-citation></ref><ref id="B55-toxins-17-00091"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yoshida</surname><given-names>K.</given-names></name>
</person-group><article-title>Botulinum Toxin Therapy for Oromandibular Dystonia and Other Movement Disorders in the Stomatognathic System</article-title><source>Toxins</source><year>2022</year><volume>14</volume><elocation-id>282</elocation-id><pub-id pub-id-type="doi">10.3390/toxins14040282</pub-id><pub-id pub-id-type="pmid">35448891</pub-id>
</element-citation></ref><ref id="B56-toxins-17-00091"><label>56.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Pihut</surname><given-names>M.</given-names></name>
</person-group><source>Efficacy of Prosthetic and Pharmacological Relaxation of Masseter Muscles as Alternative Methods of Treatment of Masticatory Organ Dysfunction</source><publisher-name>Monograph</publisher-name><publisher-loc>Krak&#x000f3;w, Poland</publisher-loc><year>2012</year></element-citation></ref><ref id="B57-toxins-17-00091"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ghavimi</surname><given-names>M.A.</given-names></name>
<name><surname>Yazdani</surname><given-names>J.</given-names></name>
<name><surname>Afzalimehr</surname><given-names>A.</given-names></name>
<name><surname>Ghoreyshizadeh</surname><given-names>A.</given-names></name>
<name><surname>Dehnad</surname><given-names>S.V.</given-names></name>
</person-group><article-title>Effect of injection of botulinum toxin on decreasing the symptoms and signs of masticatory muscles in patients with temporomandibular dysfunction</article-title><source>J. Dent. Res. Dent. Clin. Dent. Prospects</source><year>2019</year><volume>13</volume><fpage>128</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.15171/joddd.2019.020</pub-id><pub-id pub-id-type="pmid">31592308</pub-id>
</element-citation></ref><ref id="B58-toxins-17-00091"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rossetto</surname><given-names>O.</given-names></name>
<name><surname>Pirazzini</surname><given-names>M.</given-names></name>
<name><surname>Montecucco</surname><given-names>C.</given-names></name>
</person-group><article-title>Botulinum neurotoxins: Genetic, structural and mechanistic insights</article-title><source>Nat. Rev. Microbiol.</source><year>2014</year><volume>12</volume><fpage>535</fpage><lpage>549</lpage><pub-id pub-id-type="doi">10.1038/nrmicro3295</pub-id><pub-id pub-id-type="pmid">24975322</pub-id>
</element-citation></ref><ref id="B59-toxins-17-00091"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kassir</surname><given-names>M.</given-names></name>
<name><surname>Babaei</surname><given-names>M.</given-names></name>
<name><surname>Hasanzadeh</surname><given-names>S.</given-names></name>
<name><surname>Rezaei Tavirani</surname><given-names>M.</given-names></name>
<name><surname>Razzaghi</surname><given-names>Z.</given-names></name>
<name><surname>Robati</surname><given-names>R.M.</given-names></name>
</person-group><article-title>Botulinium toxin applications in the lower face and neck: A comprehensive review</article-title><source>J. Cosmet. Dermatol.</source><year>2024</year><volume>23</volume><fpage>1205</fpage><lpage>1216</lpage><pub-id pub-id-type="doi">10.1111/jocd.16116</pub-id><pub-id pub-id-type="pmid">38059697</pub-id>
</element-citation></ref><ref id="B60-toxins-17-00091"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kundu</surname><given-names>N.</given-names></name>
<name><surname>Kothari</surname><given-names>R.</given-names></name>
<name><surname>Shah</surname><given-names>N.</given-names></name>
<name><surname>Sandhu</surname><given-names>S.</given-names></name>
<name><surname>Tripathy</surname><given-names>D.M.</given-names></name>
<name><surname>Galadari</surname><given-names>H.</given-names></name>
<name><surname>Gold</surname><given-names>M.H.</given-names></name>
<name><surname>Goldman</surname><given-names>M.P.</given-names></name>
<name><surname>Kassir</surname><given-names>M.</given-names></name>
<name><surname>Schepler</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Efficacy of botulinum toxin in masseter muscle hypertrophy for lower face contouring</article-title><source>J. Cosmet. Dermatol.</source><year>2022</year><volume>21</volume><fpage>1849</fpage><lpage>1856</lpage><pub-id pub-id-type="doi">10.1111/jocd.14858</pub-id><pub-id pub-id-type="pmid">35176198</pub-id>
</element-citation></ref><ref id="B61-toxins-17-00091"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ozdemir Cetinkaya</surname><given-names>P.</given-names></name>
<name><surname>Karaosmanoglu</surname><given-names>N.</given-names></name>
<name><surname>&#x000d6;zkesici Kurt</surname><given-names>B.</given-names></name>
<name><surname>Aksu Cerman</surname><given-names>A.</given-names></name>
<name><surname>Altunay</surname><given-names>I.K.</given-names></name>
</person-group><article-title>Functional and esthetic effects of botulinum toxin injection into the masseter muscles: Evaluation of 80 patients from a dermatological perspective</article-title><source>Int. J. Dermatol.</source><year>2025</year><volume>64</volume><fpage>149</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1111/ijd.17282</pub-id><pub-id pub-id-type="pmid">38837386</pub-id>
</element-citation></ref><ref id="B62-toxins-17-00091"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chang</surname><given-names>C.-S.</given-names></name>
<name><surname>Lin</surname><given-names>S.</given-names></name>
<name><surname>Wallace</surname><given-names>C.G.</given-names></name>
<name><surname>Hsiao</surname><given-names>Y.-C.</given-names></name>
<name><surname>Lin</surname><given-names>C.-M.</given-names></name>
<name><surname>Kang</surname><given-names>G.C.-W.</given-names></name>
<name><surname>Chen</surname><given-names>Z.-C.</given-names></name>
<name><surname>Chen</surname><given-names>P.K.-T.</given-names></name>
<name><surname>Lo</surname><given-names>L.-J.</given-names></name>
<name><surname>Chen</surname><given-names>Y.-R.</given-names></name>
<etal/>
</person-group><article-title>Masseter muscle volume changes evaluated by 3-dimensional computed tomography after repeated botulinum toxin a injections in patients with square facial morphology</article-title><source>Ann. Plast. Surg.</source><year>2019</year><volume>82</volume><issue>(Suppl. S1)</issue><fpage>S29</fpage><lpage>S32</lpage><pub-id pub-id-type="doi">10.1097/SAP.0000000000001705</pub-id><pub-id pub-id-type="pmid">30540604</pub-id>
</element-citation></ref><ref id="B63-toxins-17-00091"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>H.H.</given-names></name>
<name><surname>Kim</surname><given-names>S.T.</given-names></name>
<name><surname>Lee</surname><given-names>K.J.</given-names></name>
<name><surname>Baik</surname><given-names>H.S.</given-names></name>
</person-group><article-title>Effect of a second injection of botulinum toxin on lower facial contouring, as evaluated using 3-dimensional laser scanning</article-title><source>Dermatol. Surg.</source><year>2015</year><volume>41</volume><fpage>439</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.1097/DSS.0000000000000291</pub-id><pub-id pub-id-type="pmid">25775445</pub-id>
</element-citation></ref><ref id="B64-toxins-17-00091"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ryoo</surname><given-names>H.J.</given-names></name>
<name><surname>Kwon</surname><given-names>H.</given-names></name>
<name><surname>Choi</surname><given-names>J.S.</given-names></name>
<name><surname>Sohn</surname><given-names>B.S.</given-names></name>
<name><surname>Yoo</surname><given-names>J.Y.</given-names></name>
<name><surname>Shim</surname><given-names>H.S.</given-names></name>
</person-group><article-title>Prospective Analysis of the Effectiveness of Targeted Botulinum Toxin Type A Injection Using an Ultrasound-Guided Single-Point Injection Technique for Lower Face Contouring</article-title><source>J. Clin. Med.</source><year>2024</year><volume>13</volume><elocation-id>5337</elocation-id><pub-id pub-id-type="doi">10.3390/jcm13175337</pub-id><pub-id pub-id-type="pmid">39274549</pub-id>
</element-citation></ref><ref id="B65-toxins-17-00091"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wan</surname><given-names>J.</given-names></name>
<name><surname>Kim</surname><given-names>J.S.</given-names></name>
<name><surname>Park</surname><given-names>Y.</given-names></name>
<name><surname>Park</surname><given-names>S.Y.</given-names></name>
<name><surname>Koppert</surname><given-names>E.</given-names></name>
<name><surname>Kim</surname><given-names>H.J.</given-names></name>
<name><surname>Yi</surname><given-names>K.H.</given-names></name>
</person-group><article-title>Novel single-entry point injection technique for masseter hypertrophy treatment using botulinum neurotoxin based on patient-reported comfort</article-title><source>J. Cosmet. Dermatol.</source><year>2024</year><volume>23</volume><fpage>3539</fpage><lpage>3543</lpage><pub-id pub-id-type="doi">10.1111/jocd.16461</pub-id><pub-id pub-id-type="pmid">39005194</pub-id>
</element-citation></ref><ref id="B66-toxins-17-00091"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>D.-W.</given-names></name>
<name><surname>Lai</surname><given-names>C.-Y.</given-names></name>
<name><surname>Chen</surname><given-names>J.-E.</given-names></name>
<name><surname>Yi</surname><given-names>C.-C.</given-names></name>
<name><surname>Chen</surname><given-names>Y.-H.</given-names></name>
<name><surname>Wang</surname><given-names>C.-H.</given-names></name>
<name><surname>Chen</surname><given-names>S.-G.</given-names></name>
</person-group><article-title>Three-Dimensional Photography for Evaluating the Effectiveness of Botulinum Toxin Injection for Masseter Hypertrophy</article-title><source>Aesthet. Plast. Surg.</source><year>2024</year><volume>48</volume><fpage>4065</fpage><lpage>4076</lpage><pub-id pub-id-type="doi">10.1007/s00266-024-03974-7</pub-id><pub-id pub-id-type="pmid">38740625</pub-id>
</element-citation></ref><ref id="B67-toxins-17-00091"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xie</surname><given-names>Y.</given-names></name>
<name><surname>Zhou</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>H.</given-names></name>
<name><surname>Cheng</surname><given-names>C.</given-names></name>
<name><surname>Herrler</surname><given-names>T.</given-names></name>
<name><surname>Li</surname><given-names>Q.</given-names></name>
</person-group><article-title>Classification of masseter hypertrophy for tailored botulinum toxin type A treatment</article-title><source>Plast. Reconstr. Surg.</source><year>2014</year><volume>134</volume><fpage>209e</fpage><lpage>218e</lpage><pub-id pub-id-type="doi">10.1097/PRS.0000000000000371</pub-id><pub-id pub-id-type="pmid">25068343</pub-id>
</element-citation></ref><ref id="B68-toxins-17-00091"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nikolis</surname><given-names>A.</given-names></name>
<name><surname>Enright</surname><given-names>K.M.</given-names></name>
<name><surname>Masouri</surname><given-names>S.</given-names></name>
<name><surname>Bernstein</surname><given-names>S.</given-names></name>
<name><surname>Antoniou</surname><given-names>C.</given-names></name>
</person-group><article-title>Prospective evaluation of incobotulinumtoxinA in the management of the masseter using two different injection techniques</article-title><source>Clin. Cosmet. Investig. Dermatol.</source><year>2018</year><volume>11</volume><fpage>347</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.2147/CCID.S164848</pub-id><pub-id pub-id-type="pmid">30034247</pub-id>
</element-citation></ref><ref id="B69-toxins-17-00091"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chang</surname><given-names>C.S.</given-names></name>
<name><surname>Bergeron</surname><given-names>L.</given-names></name>
<name><surname>Yu</surname><given-names>C.C.</given-names></name>
<name><surname>Chen</surname><given-names>P.K.</given-names></name>
<name><surname>Chen</surname><given-names>Y.R.</given-names></name>
</person-group><article-title>Mandible changes evaluated by computed tomography following botulinum toxin A injections in square-faced patients</article-title><source>Aesthet. Plast. Surg.</source><year>2011</year><volume>35</volume><fpage>452</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.1007/s00266-010-9624-5</pub-id></element-citation></ref><ref id="B70-toxins-17-00091"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>N.H.</given-names></name>
<name><surname>Chung</surname><given-names>J.H.</given-names></name>
<name><surname>Park</surname><given-names>R.H.</given-names></name>
<name><surname>Park</surname><given-names>J.B.</given-names></name>
</person-group><article-title>The use of botulinum toxin type A in aesthetic mandibular contouring</article-title><source>Plast. Reconstr. Surg.</source><year>2005</year><volume>115</volume><fpage>919</fpage><lpage>930</lpage><pub-id pub-id-type="doi">10.1097/01.PRS.0000153236.79775.A0</pub-id><pub-id pub-id-type="pmid">15731696</pub-id>
</element-citation></ref><ref id="B71-toxins-17-00091"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Popescu</surname><given-names>M.N.</given-names></name>
<name><surname>Beiu</surname><given-names>C.</given-names></name>
<name><surname>Iliescu</surname><given-names>C.A.</given-names></name>
<name><surname>Racovi&#x0021b;&#x00103;</surname><given-names>A.</given-names></name>
<name><surname>Berteanu</surname><given-names>M.</given-names></name>
<name><surname>Iliescu</surname><given-names>M.G.</given-names></name>
<name><surname>St&#x00103;nescu</surname><given-names>A.M.A.</given-names></name>
<name><surname>Radaschin</surname><given-names>D.S.</given-names></name>
<name><surname>Popa</surname><given-names>L.G.</given-names></name>
</person-group><article-title>Ultrasound-Guided Botulinum Toxin-A Injections into the Masseter Muscle for Both Medical and Aesthetic Purposes</article-title><source>Toxins</source><year>2024</year><volume>16</volume><elocation-id>413</elocation-id><pub-id pub-id-type="doi">10.3390/toxins16100413</pub-id><pub-id pub-id-type="pmid">39453189</pub-id>
</element-citation></ref><ref id="B72-toxins-17-00091"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de Souza Nobre</surname><given-names>B.B.</given-names></name>
<name><surname>Rezende</surname><given-names>L.</given-names></name>
<name><surname>Barbosa C&#x000e2;mara-Souza</surname><given-names>M.</given-names></name>
<name><surname>Sanchez-Ayala</surname><given-names>A.</given-names></name>
<name><surname>Blass</surname><given-names>R.</given-names></name>
<name><surname>Carbone</surname><given-names>A.C.</given-names></name>
<name><surname>Manso</surname><given-names>A.C.</given-names></name>
<name><surname>Ernberg</surname><given-names>M.</given-names></name>
<name><surname>Christidis</surname><given-names>N.</given-names></name>
<name><surname>De la Torre Canales</surname><given-names>G.</given-names></name>
</person-group><article-title>Exploring botulinum toxin&#x02019;s impact on masseter hypertrophy: A randomized, triple-blinded clinical trial</article-title><source>Sci. Rep.</source><year>2024</year><volume>14</volume><elocation-id>14522</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-024-65395-5</pub-id><pub-id pub-id-type="pmid">38914688</pub-id>
</element-citation></ref><ref id="B73-toxins-17-00091"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Tsai</surname><given-names>C.H.</given-names></name>
<name><surname>Bae</surname><given-names>T.H.</given-names></name>
<name><surname>Huang</surname><given-names>C.Y.</given-names></name>
<name><surname>Chen</surname><given-names>C.</given-names></name>
<name><surname>Kang</surname><given-names>Y.N.</given-names></name>
<name><surname>Chiu</surname><given-names>W.K.</given-names></name>
</person-group><article-title>Effectiveness of Botulinum Toxin Injection on Bruxism: A Systematic Review and Meta-analysis of Randomized Controlled Trials</article-title><source>Aesthet. Plast. Surg.</source><year>2023</year><volume>47</volume><fpage>775</fpage><lpage>790</lpage><pub-id pub-id-type="doi">10.1007/s00266-023-03256-8</pub-id></element-citation></ref><ref id="B74-toxins-17-00091"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rathod</surname><given-names>N.N.</given-names></name>
<name><surname>John</surname><given-names>R.S.</given-names></name>
</person-group><article-title>Botulinum Toxin Injection for Masseteric Hypertrophy Using 6 Point Injection Technique&#x02014;A Case Report. Proposal of a Clinical Technique to Quantify Prognosis</article-title><source>Clin. Cosmet. Investig. Dent.</source><year>2023</year><volume>15</volume><fpage>45</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.2147/CCIDE.S396057</pub-id></element-citation></ref><ref id="B75-toxins-17-00091"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chirico</surname><given-names>F.</given-names></name>
<name><surname>Bove</surname><given-names>P.</given-names></name>
<name><surname>Fragola</surname><given-names>R.</given-names></name>
<name><surname>Cosenza</surname><given-names>A.</given-names></name>
<name><surname>De Falco</surname><given-names>N.</given-names></name>
<name><surname>Giudice</surname><given-names>G.L.</given-names></name>
<name><surname>Audino</surname><given-names>G.</given-names></name>
<name><surname>Rauso</surname><given-names>G.M.</given-names></name>
</person-group><article-title>Biphasic injection for masseter muscle reduction with botulinum toxin</article-title><source>Appl. Sci.</source><year>2021</year><volume>11</volume><elocation-id>6478</elocation-id><pub-id pub-id-type="doi">10.3390/app11146478</pub-id></element-citation></ref><ref id="B76-toxins-17-00091"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Seok</surname><given-names>J.</given-names></name>
<name><surname>Koh</surname><given-names>Y.G.</given-names></name>
<name><surname>Hong</surname><given-names>J.K.</given-names></name>
<name><surname>Yun</surname><given-names>S.H.</given-names></name>
<name><surname>Kim</surname><given-names>D.H.</given-names></name>
<name><surname>Son</surname><given-names>H.S.</given-names></name>
<name><surname>Choi</surname><given-names>S.Y.</given-names></name>
<name><surname>Yoo</surname><given-names>K.H.</given-names></name>
<name><surname>Lee</surname><given-names>Y.W.</given-names></name>
<name><surname>Kim</surname><given-names>B.J.</given-names></name>
</person-group><article-title>Efficacy and Safety of PrabotulinumtoxinA in Subjects With Benign Masseteric Hypertrophy: A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase 3 Trial and Open-Label Extension Study</article-title><source>Dermatol. Surg.</source><year>2024</year><volume>50</volume><fpage>527</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1097/DSS.0000000000004146</pub-id><pub-id pub-id-type="pmid">38518110</pub-id>
</element-citation></ref><ref id="B77-toxins-17-00091"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>De la Torre Canales</surname><given-names>G.</given-names></name>
<name><surname>Poluha</surname><given-names>R.L.</given-names></name>
<name><surname>Bonjardim</surname><given-names>L.R.</given-names></name>
<name><surname>Ernberg</surname><given-names>M.</given-names></name>
<name><surname>Conti</surname><given-names>P.C.R.</given-names></name>
</person-group><article-title>Botulinum toxin-A effects on pain, somatosensory and psychosocial features of patients with refractory masticatory myofascial pain: A randomized double-blind clinical trial</article-title><source>Sci. Rep.</source><year>2024</year><volume>14</volume><elocation-id>4201</elocation-id><pub-id pub-id-type="pmid">38378855</pub-id>
</element-citation></ref><ref id="B78-toxins-17-00091"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gil-Martinez</surname><given-names>A.</given-names></name>
<name><surname>Paris-Alemany</surname><given-names>A.</given-names></name>
<name><surname>L&#x000f3;pez-De-Uralde-Villanueva</surname><given-names>I.</given-names></name>
<name><surname>La Touche</surname><given-names>R.</given-names></name>
</person-group><article-title>Management of Pain in Patients with Temporomandibular Disorder (TMD): Challenges and Solutions</article-title><source>J. Pain Res.</source><year>2018</year><volume>11</volume><fpage>571</fpage><lpage>587</lpage><pub-id pub-id-type="doi">10.2147/JPR.S127950</pub-id><pub-id pub-id-type="pmid">29588615</pub-id>
</element-citation></ref><ref id="B79-toxins-17-00091"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kaya</surname><given-names>D.I.</given-names></name>
<name><surname>Ataoglu</surname><given-names>H.</given-names></name>
</person-group><article-title>Botulinum Toxin Treatment of Temporomandibular Joint Pain in Patients with Bruxism: A Prospective and Randomized Clinical Study. Niger</article-title><source>J. Clin. Pract.</source><year>2021</year><volume>24</volume><fpage>412</fpage><lpage>417</lpage><pub-id pub-id-type="doi">10.4103/njcp.njcp_251_20</pub-id></element-citation></ref><ref id="B80-toxins-17-00091"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hosgor</surname><given-names>H.</given-names></name>
<name><surname>Altindis</surname><given-names>S.</given-names></name>
</person-group><article-title>Efficacy of botulinum toxin in the management of temporomandibular myofascial pain and sleep bruxism</article-title><source>J. Korean Assoc. Oral Maxillofac. Surg.</source><year>2020</year><volume>46</volume><fpage>335</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.5125/jkaoms.2020.46.5.335</pub-id><pub-id pub-id-type="pmid">33122458</pub-id>
</element-citation></ref><ref id="B81-toxins-17-00091"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Koo</surname><given-names>H.J.</given-names></name>
<name><surname>Hu</surname><given-names>H.</given-names></name>
<name><surname>Kim</surname><given-names>W.</given-names></name>
<name><surname>Kim</surname><given-names>J.S.</given-names></name>
<name><surname>Kim</surname><given-names>H.J.</given-names></name>
<name><surname>Yi</surname><given-names>K.H.</given-names></name>
</person-group><article-title>Do repetitive botulinum neurotoxin injections induce muscle fibrosis? Sonographic observation of the masseter muscle</article-title><source>J. Cosmet. Dermatol.</source><year>2024</year><volume>23</volume><fpage>434</fpage><lpage>440</lpage><pub-id pub-id-type="doi">10.1111/jocd.16022</pub-id><pub-id pub-id-type="pmid">37942679</pub-id>
</element-citation></ref><ref id="B82-toxins-17-00091"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mandel</surname><given-names>L.</given-names></name>
<name><surname>Tharakan</surname><given-names>M.</given-names></name>
</person-group><article-title>Treatment of unilateral masseteric hypertrophy with botulinum toxin: Case report</article-title><source>J. Oral Maxillofac. Surg.</source><year>1999</year><volume>57</volume><fpage>1017</fpage><lpage>1019</lpage><pub-id pub-id-type="doi">10.1016/S0278-2391(99)90029-0</pub-id><pub-id pub-id-type="pmid">10437733</pub-id>
</element-citation></ref><ref id="B83-toxins-17-00091"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tartaro</surname><given-names>G.</given-names></name>
<name><surname>Rauso</surname><given-names>R.</given-names></name>
<name><surname>Santagata</surname><given-names>M.</given-names></name>
<name><surname>Santillo</surname><given-names>V.</given-names></name>
<name><surname>Itro</surname><given-names>A.</given-names></name>
</person-group><article-title>Lower facial contouring with botulinum toxin type A</article-title><source>J. Craniofacial Surg.</source><year>2008</year><volume>19</volume><fpage>1613</fpage><lpage>1617</lpage><pub-id pub-id-type="doi">10.1097/SCS.0b013e31818973c8</pub-id><pub-id pub-id-type="pmid">19098563</pub-id>
</element-citation></ref><ref id="B84-toxins-17-00091"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baldwin</surname><given-names>M.C.</given-names></name>
<name><surname>Liu</surname><given-names>Z.J.</given-names></name>
<name><surname>Rafferty</surname><given-names>K.L.</given-names></name>
<name><surname>Keith</surname><given-names>A.</given-names></name>
<name><surname>Tamasas</surname><given-names>B.</given-names></name>
<name><surname>Kaiyala</surname><given-names>K.</given-names></name>
<name><surname>Herring</surname><given-names>S.W.</given-names></name>
</person-group><article-title>Botulinum toxin in the masseter muscle: Lingering effects of denervation</article-title><source>Anat. Rec.</source><year>2022</year><volume>305</volume><fpage>1215</fpage><lpage>1230</lpage><pub-id pub-id-type="doi">10.1002/ar.24756</pub-id><pub-id pub-id-type="pmid">34486243</pub-id>
</element-citation></ref><ref id="B85-toxins-17-00091"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mkhitaryan</surname><given-names>L.</given-names></name>
<name><surname>Alcolea</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Prospective Clinical Study and Ultrasound Assessment in Patients with Bruxism Treated with Botulinum Toxin</article-title><source>Aesthetic Med.</source><year>2020</year><volume>6</volume><fpage>25</fpage><lpage>34</lpage></element-citation></ref><ref id="B86-toxins-17-00091"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>H.J.</given-names></name>
<name><surname>Kang</surname><given-names>I.W.</given-names></name>
<name><surname>Seo</surname><given-names>K.K.</given-names></name>
<name><surname>Choi</surname><given-names>Y.J.</given-names></name>
<name><surname>Kim</surname><given-names>S.T.</given-names></name>
<name><surname>Hu</surname><given-names>K.S.</given-names></name>
<name><surname>Kim</surname><given-names>H.J.</given-names></name>
</person-group><article-title>The Anatomical Basis of Paradoxical Masseteric Bulging after Botulinum Neurotoxin Type a Injection</article-title><source>Toxins</source><year>2017</year><volume>9</volume><elocation-id>14</elocation-id><pub-id pub-id-type="doi">10.3390/toxins9010014</pub-id><pub-id pub-id-type="pmid">28042813</pub-id>
</element-citation></ref><ref id="B87-toxins-17-00091"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ho</surname><given-names>W.W.S.</given-names></name>
<name><surname>Chan</surname><given-names>L.</given-names></name>
<name><surname>Corduff</surname><given-names>N.</given-names></name>
<name><surname>Lau</surname><given-names>W.-T.</given-names></name>
<name><surname>Martin</surname><given-names>M.U.</given-names></name>
<name><surname>Tay</surname><given-names>C.M.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Wu</surname><given-names>R.</given-names></name>
</person-group><article-title>Addressing the Real-World Challenges of Immunoresistance to Botulinum Neurotoxin A in Aesthetic Practice: Insights and Recommendations from a Panel Discussion in Hong Kong</article-title><source>Toxins</source><year>2023</year><volume>15</volume><elocation-id>456</elocation-id><pub-id pub-id-type="doi">10.3390/toxins15070456</pub-id><pub-id pub-id-type="pmid">37505725</pub-id>
</element-citation></ref><ref id="B88-toxins-17-00091"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shi</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>C.</given-names></name>
<name><surname>Zhou</surname><given-names>J.</given-names></name>
<name><surname>Guo</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>G.</given-names></name>
<name><surname>You</surname><given-names>M.</given-names></name>
</person-group><article-title>An Ultrasonographic Analysis of the Deep Inferior Tendon in the Masseter Muscle: Implications for Botulinum Toxin Injections</article-title><source>Toxins</source><year>2024</year><volume>16</volume><elocation-id>391</elocation-id><pub-id pub-id-type="doi">10.3390/toxins16090391</pub-id><pub-id pub-id-type="pmid">39330849</pub-id>
</element-citation></ref><ref id="B89-toxins-17-00091"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shim</surname><given-names>Y.J.</given-names></name>
<name><surname>Lee</surname><given-names>H.J.</given-names></name>
<name><surname>Park</surname><given-names>K.J.</given-names></name>
<name><surname>Kim</surname><given-names>H.T.</given-names></name>
<name><surname>Hong</surname><given-names>I.H.</given-names></name>
<name><surname>Kim</surname><given-names>S.T.</given-names></name>
</person-group><article-title>Botulinum Toxin Therapy for Managing Sleep Bruxism: A Randomized and Placebo-Controlled Trial</article-title><source>Toxins</source><year>2020</year><volume>12</volume><elocation-id>168</elocation-id><pub-id pub-id-type="doi">10.3390/toxins12030168</pub-id><pub-id pub-id-type="pmid">32182879</pub-id>
</element-citation></ref><ref id="B90-toxins-17-00091"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>L.D.</given-names></name>
<name><surname>Liu</surname><given-names>Q.</given-names></name>
<name><surname>Zou</surname><given-names>D.R.</given-names></name>
<name><surname>Yu</surname><given-names>L.F.</given-names></name>
</person-group><article-title>Occlusal force characteristics of masseteric muscles after intramuscular injection of botulinum toxin A(BTX&#x02014;A)for treatment of temporomandibular disorder</article-title><source>Br. J. Oral Maxillofac. Surg.</source><year>2016</year><volume>54</volume><fpage>736</fpage><lpage>740</lpage><pub-id pub-id-type="doi">10.1016/j.bjoms.2016.04.008</pub-id><pub-id pub-id-type="pmid">27138229</pub-id>
</element-citation></ref><ref id="B91-toxins-17-00091"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Diracoglu</surname><given-names>D.</given-names></name>
<name><surname>Sahbaz</surname><given-names>T.</given-names></name>
<name><surname>Alptekin</surname><given-names>K.</given-names></name>
<name><surname>Dogan</surname><given-names>N.</given-names></name>
</person-group><article-title>Effects of ultrasound-assisted botulinum neurotoxin-A injection in patients with bruxism and masseter hypertrophy</article-title><source>Turk. J. Phys. Med. Rehabil.</source><year>2021</year><volume>67</volume><fpage>351</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.5606/tftrd.2021.6288</pub-id><pub-id pub-id-type="pmid">34870123</pub-id>
</element-citation></ref><ref id="B92-toxins-17-00091"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Park</surname><given-names>Y.</given-names></name>
<name><surname>Ku</surname><given-names>S.K.</given-names></name>
<name><surname>Lee</surname><given-names>D.H.</given-names></name>
<name><surname>Kim</surname><given-names>S.T.</given-names></name>
</person-group><article-title>Combined Effects of Botulinum Toxin Injection and Oral Appliance Therapy on Lower Facial Contouring: A Randomized Controlled Trial</article-title><source>J. Clin. Med.</source><year>2022</year><volume>11</volume><elocation-id>4092</elocation-id><pub-id pub-id-type="doi">10.3390/jcm11144092</pub-id><pub-id pub-id-type="pmid">35887855</pub-id>
</element-citation></ref><ref id="B93-toxins-17-00091"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>S.J.</given-names></name>
<name><surname>McCall</surname><given-names>W.D.</given-names><suffix>Jr.</suffix></name>
<name><surname>Kim</surname><given-names>Y.K.</given-names></name>
<name><surname>Chung</surname><given-names>S.C.</given-names></name>
<name><surname>Chung</surname><given-names>J.W.</given-names></name>
</person-group><article-title>Effect of botulinum toxin injection on nocturnal bruxism: A randomized controlled trial</article-title><source>Am. J. Phys. Med. Rehabil.</source><year>2010</year><volume>89</volume><fpage>16</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1097/PHM.0b013e3181bc0c78</pub-id><pub-id pub-id-type="pmid">19855255</pub-id>
</element-citation></ref><ref id="B94-toxins-17-00091"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jung</surname><given-names>B.K.</given-names></name>
<name><surname>Park</surname><given-names>H.</given-names></name>
<name><surname>Cheon</surname><given-names>Y.W.</given-names></name>
<name><surname>Yun</surname><given-names>I.S.</given-names></name>
<name><surname>Choi</surname><given-names>J.-W.</given-names></name>
<name><surname>Kim</surname><given-names>H.J.</given-names></name>
<name><surname>Lee</surname><given-names>M.Y.</given-names></name>
<name><surname>Kang</surname><given-names>B.S.</given-names></name>
<name><surname>Kang</surname><given-names>T.J.</given-names></name>
</person-group><article-title>Clinical investigation of botulinum toxin (prabotulinumtoxin A) for bruxism related to masseter muscle hypertrophy: A prospective study</article-title><source>J. Cranio-Maxillofac. Surg.</source><year>2023</year><volume>51</volume><fpage>332</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1016/j.jcms.2023.05.005</pub-id><pub-id pub-id-type="pmid">37353404</pub-id>
</element-citation></ref><ref id="B95-toxins-17-00091"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alwayli</surname><given-names>H.</given-names></name>
<name><surname>Abdulrahman</surname><given-names>B.I.</given-names></name>
<name><surname>Rastogi</surname><given-names>S.</given-names></name>
</person-group><article-title>Does botulinum toxin have any role in the management of chronic pain associated with bruxism?</article-title><source>Cranio</source><year>2024</year><volume>42</volume><fpage>215</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1080/08869634.2021.1949536</pub-id><pub-id pub-id-type="pmid">34259618</pub-id>
</element-citation></ref><ref id="B96-toxins-17-00091"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guo</surname><given-names>Y.</given-names></name>
<name><surname>Diao</surname><given-names>X.</given-names></name>
<name><surname>Dong</surname><given-names>D.</given-names></name>
<name><surname>Xia</surname><given-names>W.</given-names></name>
<name><surname>Liu</surname><given-names>T.</given-names></name>
<name><surname>Zhou</surname><given-names>Y.</given-names></name>
<name><surname>Zhu</surname><given-names>J.</given-names></name>
<name><surname>Chen</surname><given-names>L.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
</person-group><article-title>Effects of Two Botulinum Toxin Type a Evaluated by Shear Wave Elastography and Electromyographic Measurements of Masseter Reduction</article-title><source>J. Craniofacial Surg.</source><year>2022</year><volume>33</volume><fpage>1450</fpage><lpage>1453</lpage><pub-id pub-id-type="doi">10.1097/SCS.0000000000008368</pub-id><pub-id pub-id-type="pmid">35758504</pub-id>
</element-citation></ref><ref id="B97-toxins-17-00091"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sendra</surname><given-names>L.A.</given-names></name>
<name><surname>Azeredo Alves Antunes</surname><given-names>L.</given-names></name>
<name><surname>Barboza</surname><given-names>E.P.</given-names></name>
</person-group><article-title>Use of botulinum neurotoxin Type A in the management of primary bruxism in adults: An updated systematic review</article-title><source>J. Prosthet. Dent.</source><year>2024</year><volume>132</volume><fpage>93</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1016/j.prosdent.2022.05.009</pub-id><pub-id pub-id-type="pmid">35779974</pub-id>
</element-citation></ref><ref id="B98-toxins-17-00091"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hong</surname><given-names>J.Y.</given-names></name>
<name><surname>Jeong</surname><given-names>G.J.</given-names></name>
<name><surname>Kwon</surname><given-names>T.R.</given-names></name>
<name><surname>Kim</surname><given-names>J.H.</given-names></name>
<name><surname>Li</surname><given-names>K.</given-names></name>
<name><surname>Kim</surname><given-names>B.J.</given-names></name>
</person-group><article-title>Efficacy and Safety of a Novel Botulinum Toxin A for Masseter Reduction: A Randomized, Double-Blind, Placebo-Controlled, Optimal Dose-Finding Study</article-title><source>Dermatol. Surg.</source><year>2021</year><volume>47</volume><fpage>e5</fpage><lpage>e9</lpage><pub-id pub-id-type="doi">10.1097/DSS.0000000000002475</pub-id><pub-id pub-id-type="pmid">33347002</pub-id>
</element-citation></ref><ref id="B99-toxins-17-00091"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Asutay</surname><given-names>F.</given-names></name>
<name><surname>Atalay</surname><given-names>Y.</given-names></name>
<name><surname>Asutay</surname><given-names>H.</given-names></name>
<name><surname>Acar</surname><given-names>A.H.</given-names></name>
</person-group><article-title>The Evaluation of the Clinical Effects of Botulinum Toxin on Nocturnal Bruxism</article-title><source>Pain Res. Manag.</source><year>2017</year><volume>2017</volume><fpage>6264146</fpage><pub-id pub-id-type="doi">10.1155/2017/6264146</pub-id><pub-id pub-id-type="pmid">28757802</pub-id>
</element-citation></ref><ref id="B100-toxins-17-00091"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sidebottom</surname><given-names>A.J.</given-names></name>
<name><surname>Patel</surname><given-names>A.A.</given-names></name>
<name><surname>Amin</surname><given-names>J.</given-names></name>
</person-group><article-title>Botulinum injection for the management of myofascial pain in the masticatory muscles. A prospective outcome study</article-title><source>Br. J. Oral Maxillofac. Surg.</source><year>2013</year><volume>51</volume><fpage>199</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1016/j.bjoms.2012.07.002</pub-id><pub-id pub-id-type="pmid">22871559</pub-id>
</element-citation></ref><ref id="B101-toxins-17-00091"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guarda-Nardini</surname><given-names>L.</given-names></name>
<name><surname>Manfredini</surname><given-names>D.</given-names></name>
<name><surname>Salamone</surname><given-names>M.</given-names></name>
<name><surname>Salmaso</surname><given-names>L.</given-names></name>
<name><surname>Tonello</surname><given-names>S.</given-names></name>
<name><surname>Ferronato</surname><given-names>G.</given-names></name>
</person-group><article-title>Efficacy of botulinum toxin in treating myofascial pain in bruxers: A controlled placebo pilot study</article-title><source>Cranio</source><year>2008</year><volume>26</volume><fpage>126</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1179/crn.2008.017</pub-id><pub-id pub-id-type="pmid">18468272</pub-id>
</element-citation></ref><ref id="B102-toxins-17-00091"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>K.</given-names></name>
<name><surname>Tan</surname><given-names>K.</given-names></name>
<name><surname>Yacovelli</surname><given-names>A.</given-names></name>
<name><surname>Bi</surname><given-names>W.G.</given-names></name>
</person-group><article-title>Effect of botulinum toxin type A on muscular temporomandibular disorder: A systematic review and meta-analysis of randomized controlled trials</article-title><source>J. Oral Rehabil.</source><year>2024</year><volume>51</volume><fpage>886</fpage><lpage>897</lpage><pub-id pub-id-type="doi">10.1111/joor.13648</pub-id><pub-id pub-id-type="pmid">38151884</pub-id>
</element-citation></ref><ref id="B103-toxins-17-00091"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Delcanho</surname><given-names>R.</given-names></name>
<name><surname>Val</surname><given-names>M.</given-names></name>
<name><surname>Guarda Nardini</surname><given-names>L.</given-names></name>
<name><surname>Manfredini</surname><given-names>D.</given-names></name>
</person-group><article-title>Botulinum Toxin for Treating Temporomandibular Disorders: What is the Evidence?</article-title><source>J. Oral Facial Pain Headache</source><year>2022</year><volume>36</volume><fpage>6</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.11607/ofph.3023</pub-id><pub-id pub-id-type="pmid">35298571</pub-id>
</element-citation></ref><ref id="B104-toxins-17-00091"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Machado</surname><given-names>D.</given-names></name>
<name><surname>Martimbianco</surname><given-names>A.L.C.</given-names></name>
<name><surname>Bussadori</surname><given-names>S.K.</given-names></name>
<name><surname>Pacheco</surname><given-names>R.L.</given-names></name>
<name><surname>Riera</surname><given-names>R.</given-names></name>
<name><surname>Santos</surname><given-names>E.M.</given-names></name>
</person-group><article-title>Botulinum toxin type a for painful temporomandibular disorders: Systematic review and meta-analysis</article-title><source>J. Pain</source><year>2020</year><volume>21</volume><fpage>281</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1016/j.jpain.2019.08.011</pub-id><pub-id pub-id-type="pmid">31513934</pub-id>
</element-citation></ref><ref id="B105-toxins-17-00091"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ramos-Herrada</surname><given-names>R.M.</given-names></name>
<name><surname>Arriola-Guill&#x000e9;n</surname><given-names>L.E.</given-names></name>
<name><surname>Atoche-Socola</surname><given-names>K.J.</given-names></name>
<name><surname>Bellini-Pereira</surname><given-names>S.A.</given-names></name>
<name><surname>Castillo</surname><given-names>A.A.D.</given-names></name>
</person-group><article-title>Effects of botulinum toxin in patients with myofascial pain related to temporomandibular joint disorders: A systematic review</article-title><source>Dent. Med. Probl.</source><year>2022</year><volume>59</volume><fpage>271</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.17219/dmp/145759</pub-id><pub-id pub-id-type="pmid">35775414</pub-id>
</element-citation></ref><ref id="B106-toxins-17-00091"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thambar</surname><given-names>S.</given-names></name>
<name><surname>Kulkarni</surname><given-names>S.</given-names></name>
<name><surname>Armstrong</surname><given-names>S.</given-names></name>
<name><surname>Nikolarakos</surname><given-names>D.</given-names></name>
</person-group><article-title>Botulinum toxin in the management of temporomandibular disorders: A systematic review</article-title><source>Br. J. Oral Maxillofac. Surg.</source><year>2020</year><volume>58</volume><fpage>508</fpage><lpage>519</lpage><pub-id pub-id-type="doi">10.1016/j.bjoms.2020.02.007</pub-id><pub-id pub-id-type="pmid">32143934</pub-id>
</element-citation></ref><ref id="B107-toxins-17-00091"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Signorini</surname><given-names>M.</given-names></name>
<name><surname>Fundar&#x000f2;</surname><given-names>S.P.</given-names></name>
<name><surname>Bertossi</surname><given-names>D.</given-names></name>
<name><surname>Cavallini</surname><given-names>M.</given-names></name>
<name><surname>Cirillo</surname><given-names>P.</given-names></name>
<name><surname>Natuzzi</surname><given-names>G.</given-names></name>
<name><surname>Quartucci</surname><given-names>S.</given-names></name>
<name><surname>Sciuto</surname><given-names>C.</given-names></name>
<name><surname>Patalano</surname><given-names>M.</given-names></name>
<name><surname>Trocchi</surname><given-names>G.</given-names></name>
</person-group><article-title>OnabotulinumtoxinA from lines to facial reshaping: A new Italian consensus report</article-title><source>J. Cosmet. Dermatol.</source><year>2022</year><volume>21</volume><fpage>550</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1111/jocd.14728</pub-id><pub-id pub-id-type="pmid">35060310</pub-id>
</element-citation></ref><ref id="B108-toxins-17-00091"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>S.</given-names></name>
<name><surname>Zhao</surname><given-names>H.</given-names></name>
<name><surname>Liu</surname><given-names>C.</given-names></name>
<name><surname>Gao</surname><given-names>X.</given-names></name>
<name><surname>Hao</surname><given-names>L.</given-names></name>
</person-group><article-title>3D Assessment of Mandibular Margin Morphological Change after BTX-A Injection for Masseter Hypertrophy: A Retrospective Study</article-title><source>Aesthet. Plast. Surg.</source><year>2024</year><pub-id pub-id-type="doi">10.1007/s00266-024-04488-y</pub-id></element-citation></ref><ref id="B109-toxins-17-00091"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rauso</surname><given-names>R.</given-names></name>
<name><surname>Lo Giudice</surname><given-names>G.</given-names></name>
<name><surname>Tartaro</surname><given-names>G.</given-names></name>
<name><surname>Zerbinati</surname><given-names>N.</given-names></name>
<name><surname>Nicoletti</surname><given-names>G.F.</given-names></name>
<name><surname>Fragola</surname><given-names>R.</given-names></name>
</person-group><article-title>Botulinum toxin type A injections for masticatory muscles hypertrophy: A systematic review</article-title><source>J. Cranio-Maxillofac. Surg.</source><year>2022</year><volume>50</volume><fpage>7</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/j.jcms.2021.09.019</pub-id></element-citation></ref><ref id="B110-toxins-17-00091"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>D.-H.</given-names></name>
<name><surname>Hong</surname><given-names>H.-S.</given-names></name>
<name><surname>Won</surname><given-names>S.-Y.</given-names></name>
<name><surname>Kim</surname><given-names>H.-J.</given-names></name>
<name><surname>Hu</surname><given-names>K.-S.</given-names></name>
<name><surname>Choi</surname><given-names>J.-H.</given-names></name>
<name><surname>Kim</surname><given-names>H.-J.</given-names></name>
</person-group><article-title>Intramuscular nerve distribution of the masseter muscle as a basis for botulinum toxin injection</article-title><source>J. Craniofacial Surg.</source><year>2010</year><volume>21</volume><fpage>588</fpage><lpage>591</lpage><pub-id pub-id-type="doi">10.1097/SCS.0b013e3181d08bb3</pub-id><pub-id pub-id-type="pmid">20489458</pub-id>
</element-citation></ref><ref id="B111-toxins-17-00091"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Peng</surname><given-names>H.P.</given-names></name>
<name><surname>Peng</surname><given-names>J.H.</given-names></name>
</person-group><article-title>Complications of botulinum toxin injection for masseter hypertrophy: Incidence rate from 2036 treatments and summary of causes and preventions</article-title><source>J. Cosmet. Dermatol.</source><year>2018</year><volume>17</volume><fpage>33</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1111/jocd.12473</pub-id><pub-id pub-id-type="pmid">29250900</pub-id>
</element-citation></ref><ref id="B112-toxins-17-00091"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ferrari</surname><given-names>A.</given-names></name>
<name><surname>Manca</surname><given-names>M.</given-names></name>
<name><surname>Tugnoli</surname><given-names>V.</given-names></name>
<name><surname>Alberto</surname><given-names>L.</given-names></name>
</person-group><article-title>Pharmacological differences and clinical implications of various botulinum toxin preparations: A critical appraisal</article-title><source>Funct. Neurol.</source><year>2018</year><volume>33</volume><fpage>7</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.11138/FNeur/2018.33.1.007</pub-id><pub-id pub-id-type="pmid">29633692</pub-id>
</element-citation></ref><ref id="B113-toxins-17-00091"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yeh</surname><given-names>Y.T.</given-names></name>
<name><surname>Peng</surname><given-names>J.H.</given-names></name>
<name><surname>Peng</surname><given-names>H.-P.</given-names></name>
</person-group><article-title>Literature review of the adverse events associated with botulinum toxin injection for the masseter muscle hypertrophy</article-title><source>J. Cosmet. Dermatol.</source><year>2018</year><volume>17</volume><fpage>675</fpage><lpage>687</lpage><pub-id pub-id-type="doi">10.1111/jocd.12721</pub-id><pub-id pub-id-type="pmid">30091170</pub-id>
</element-citation></ref><ref id="B114-toxins-17-00091"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shome</surname><given-names>D.</given-names></name>
<name><surname>Khare</surname><given-names>S.</given-names></name>
<name><surname>Kapoor</surname><given-names>R.</given-names></name>
</person-group><article-title>Efficacy of Botulinum Toxin in Treating Asian Indian Patients with Masseter Hypertrophy: A 4-Year Follow-Up Study</article-title><source>Plast. Reconstr. Surg.</source><year>2019</year><volume>144</volume><fpage>390e</fpage><lpage>396e</lpage><pub-id pub-id-type="doi">10.1097/PRS.0000000000005944</pub-id></element-citation></ref><ref id="B115-toxins-17-00091"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guida</surname><given-names>S.</given-names></name>
</person-group><article-title>Neurotoxin in the Lower Third of the Face</article-title><source>Dermatol. Clin.</source><year>2023</year><volume>42</volume><fpage>63</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">37977685</pub-id>
</element-citation></ref><ref id="B116-toxins-17-00091"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bae</surname><given-names>J.H.</given-names></name>
<name><surname>Choi</surname><given-names>D.Y.</given-names></name>
<name><surname>Lee</surname><given-names>J.G.</given-names></name>
</person-group><article-title>The risorius muscle: Anatomic considerations with reference to botulinum neurotoxin injection for masseteric hypertrophy</article-title><source>Dermatol. Surg.</source><year>2014</year><volume>40</volume><fpage>1334</fpage><lpage>1339</lpage><pub-id pub-id-type="doi">10.1097/DSS.0000000000000223</pub-id><pub-id pub-id-type="pmid">25393348</pub-id>
</element-citation></ref><ref id="B117-toxins-17-00091"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Frevert</surname><given-names>J.</given-names></name>
<name><surname>Dressler</surname><given-names>D.</given-names></name>
</person-group><article-title>Complexing proteins in botulinum toxin type A drugs: A help or a hindrance?</article-title><source>Biologics</source><year>2010</year><volume>4</volume><fpage>325</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.2147/BTT.S14902</pub-id><pub-id pub-id-type="pmid">21209727</pub-id>
</element-citation></ref><ref id="B118-toxins-17-00091"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dressler</surname><given-names>D.</given-names></name>
</person-group><article-title>Botulinum toxin drugs: Brief history and outlook</article-title><source>J. Neural Transm.</source><year>2015</year><volume>119</volume><fpage>877</fpage><lpage>879</lpage><pub-id pub-id-type="doi">10.1007/s00702-015-1478-1</pub-id><pub-id pub-id-type="pmid">26559824</pub-id>
</element-citation></ref><ref id="B119-toxins-17-00091"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yiannakopoulou</surname><given-names>E.</given-names></name>
</person-group><article-title>Serious and long-term adverse events associated with the therapeutic and cosmetic use of botulinum toxin</article-title><source>Pharmacology</source><year>2015</year><volume>95</volume><fpage>65</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1159/000370245</pub-id><pub-id pub-id-type="pmid">25613637</pub-id>
</element-citation></ref><ref id="B120-toxins-17-00091"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rahman</surname><given-names>E.</given-names></name>
<name><surname>Carruthers</surname><given-names>J.D.A.</given-names></name>
</person-group><article-title>Immunogenicity of Botulinum Toxin A: Insights</article-title><source>Dermatol. Surg.</source><year>2024</year><volume>50</volume><fpage>S117</fpage><lpage>S126</lpage><pub-id pub-id-type="doi">10.1097/DSS.0000000000004293</pub-id><pub-id pub-id-type="pmid">39196845</pub-id>
</element-citation></ref><ref id="B121-toxins-17-00091"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Borodic</surname><given-names>G.</given-names></name>
</person-group><article-title>Botulinum toxin, immunologic considerations with long-term repeated use, with emphasis on cosmetic applications</article-title><source>Facial Plast. Surg. Clin. N. Am.</source><year>2007</year><volume>15</volume><fpage>11</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.fsc.2006.10.001</pub-id><pub-id pub-id-type="pmid">17317551</pub-id>
</element-citation></ref><ref id="B122-toxins-17-00091"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Erdil</surname><given-names>D.</given-names></name>
<name><surname>Bagis</surname><given-names>N.</given-names></name>
<name><surname>Eren</surname><given-names>H.</given-names></name>
<name><surname>Camgoz</surname><given-names>M.</given-names></name>
<name><surname>Orhan</surname><given-names>K.</given-names></name>
</person-group><article-title>The Evaluation of the Relationship between Changes in Masseter Muscle Thickness and Tooth Clenching Habits of Bruxism Patients Treated with Botulinum Toxin A</article-title><source>J. Med. Ultrasound</source><year>2022</year><volume>31</volume><fpage>22</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.4103/jmu.jmu_51_22</pub-id><pub-id pub-id-type="pmid">37180633</pub-id>
</element-citation></ref><ref id="B123-toxins-17-00091"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moussa</surname><given-names>M.S.</given-names></name>
<name><surname>Bachour</surname><given-names>D.</given-names></name>
<name><surname>Komarova</surname><given-names>S.V.</given-names></name>
</person-group><article-title>Adverse effect of botulinum toxin-A injections on mandibular bone: A systematic review and meta-analysis</article-title><source>J. Oral Rehabil.</source><year>2024</year><volume>51</volume><fpage>404</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.1111/joor.13590</pub-id><pub-id pub-id-type="pmid">37668276</pub-id>
</element-citation></ref><ref id="B124-toxins-17-00091"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hong</surname><given-names>S.W.</given-names></name>
<name><surname>Kang</surname><given-names>J.H.</given-names></name>
</person-group><article-title>Decreased mandibular cortical bone quality after botulinum toxin injections in masticatory muscles in female adults</article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><elocation-id>3623</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-020-60554-w</pub-id><pub-id pub-id-type="pmid">32107437</pub-id>
</element-citation></ref><ref id="B125-toxins-17-00091"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tsai</surname><given-names>C.Y.</given-names></name>
<name><surname>Shyr</surname><given-names>Y.M.</given-names></name>
<name><surname>Chiu</surname><given-names>W.C.</given-names></name>
<name><surname>Lee</surname><given-names>C.M.</given-names></name>
</person-group><article-title>Bone changes in the mandible following botulinum neurotoxin injections</article-title><source>Eur. J. Orthod.</source><year>2011</year><volume>33</volume><fpage>32</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1093/ejo/cjq029</pub-id><pub-id pub-id-type="pmid">20660130</pub-id>
</element-citation></ref><ref id="B126-toxins-17-00091"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kahn</surname><given-names>A.</given-names></name>
<name><surname>K&#x000fc;n-Darbois</surname><given-names>J.D.</given-names></name>
<name><surname>Bertin</surname><given-names>H.</given-names></name>
<name><surname>Corre</surname><given-names>P.</given-names></name>
<name><surname>Chappard</surname><given-names>D.</given-names></name>
</person-group><article-title>Mandibular bone effects of botulinum toxin injections in masticatory muscles in adult</article-title><source>Oral Surg. Oral Med. Oral Pathol. Oral Radiol.</source><year>2020</year><volume>129</volume><fpage>100</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1016/j.oooo.2019.03.007</pub-id><pub-id pub-id-type="pmid">31227452</pub-id>
</element-citation></ref><ref id="B127-toxins-17-00091"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Zheng</surname><given-names>Q.</given-names></name>
<name><surname>Lin</surname><given-names>J.</given-names></name>
<name><surname>Su</surname><given-names>X.</given-names></name>
<name><surname>Zhuang</surname><given-names>J.</given-names></name>
<name><surname>Wei</surname><given-names>Q.</given-names></name>
<name><surname>Hu</surname><given-names>J.</given-names></name>
</person-group><article-title>Mild Allergic Reactions after Botulinum Toxin Injection: A Case Series and Literature Review</article-title><source>Plast. Reconstr. Surg. Glob. Open</source><year>2024</year><volume>12</volume><fpage>e5845</fpage><pub-id pub-id-type="doi">10.1097/GOX.0000000000005845</pub-id><pub-id pub-id-type="pmid">38798928</pub-id>
</element-citation></ref></ref-list></back><floats-group><table-wrap position="float" id="toxins-17-00091-t001"><object-id pub-id-type="pii">toxins-17-00091-t001_Table 1</object-id><label>Table 1</label><caption><p>Injection techniques and doses for masseter muscle hypertrophy.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Injection Technique</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Number of Injection Sites</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Total Dose</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Toxin Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Notes (with References)</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multi-point injection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3&#x02013;5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24&#x02013;60 U (onabotulinum/incobotulinum toxin A)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Onabotulinum/Incobotulinum</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ensures uniform toxin distribution within the muscle and reduces asymmetry risks [<xref rid="B91-toxins-17-00091" ref-type="bibr">91</xref>,<xref rid="B112-toxins-17-00091" ref-type="bibr">112</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single-point injection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20&#x02013;40 U (onabotulinum toxin A)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Onabotulinum</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Faster and less painful; may result in uneven muscle reduction [<xref rid="B108-toxins-17-00091" ref-type="bibr">108</xref>,<xref rid="B113-toxins-17-00091" ref-type="bibr">113</xref>,<xref rid="B114-toxins-17-00091" ref-type="bibr">114</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ultrasound-guided injection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Variable</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20&#x02013;60 U</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Onabotulinum/Incobotulinum</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increases precision, reduces diffusion risks, and ensures accurate delivery [<xref rid="B62-toxins-17-00091" ref-type="bibr">62</xref>,<xref rid="B91-toxins-17-00091" ref-type="bibr">91</xref>,<xref rid="B108-toxins-17-00091" ref-type="bibr">108</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multi-muscle protocol<break/>(masseter, temporalis, and in some cases, the pterygoid muscles)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Variable</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20&#x02013;60 U (masseter, temporalis, pterygoid)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Onabotulinum</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Associated with significant pain reduction in TMD patients [<xref rid="B71-toxins-17-00091" ref-type="bibr">71</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Abobotulinum toxin A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60&#x02013;300 U</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Abobotulinum</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BoNT-A neurotoxin is estimated at 137 units/ng for onabotulinumtoxinA, 154 units/ng for abobotulinumtoxinA, and 227 units/ng for incobotulinumtoxinA [<xref rid="B112-toxins-17-00091" ref-type="bibr">112</xref>,<xref rid="B113-toxins-17-00091" ref-type="bibr">113</xref>,<xref rid="B114-toxins-17-00091" ref-type="bibr">114</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High-dose injection </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Variable</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Up to 400 U every 3 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">All types</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Effective for severe TMD; no significant increase in adverse events with higher doses [<xref rid="B14-toxins-17-00091" ref-type="bibr">14</xref>,<xref rid="B115-toxins-17-00091" ref-type="bibr">115</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Repeat treatment </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Variable</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15&#x02013;30 U per side</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Onabotulinum</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Muscle thickness and dosage decrease with repeated injections over time [<xref rid="B116-toxins-17-00091" ref-type="bibr">116</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Combination therapy (masseter + others)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60&#x02013;100 U (masseter, temporalis, pterygoid)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Onabotulinum</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Combined improvement in TMD symptoms and facial contouring [<xref rid="B71-toxins-17-00091" ref-type="bibr">71</xref>,<xref rid="B92-toxins-17-00091" ref-type="bibr">92</xref>]</td></tr></tbody></table></table-wrap><table-wrap position="float" id="toxins-17-00091-t002"><object-id pub-id-type="pii">toxins-17-00091-t002_Table 2</object-id><label>Table 2</label><caption><p>Side effects of botulinum toxin treatment for masseter muscle hypertrophy.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Incidence</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Side Effects</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Management</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Common (~30&#x02013;50%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mild pain at injection site, temporary muscle weakness</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Analgesics, reassurance; dose adjustment</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Occasional (~2&#x02013;15%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Facial asymmetry, bruising, headache, altered chewing mechanics, sunken cheeks</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Precise injection techniques; local compression; analgesics; tailor dosage to individual anatomy</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rare (~0.2&#x02013;2.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Incipient sagging of cheeks/skin, sagging of jaw soft tissues</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Use lower doses; distribute sessions; consider depressor muscle injections</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rare (~&#x0003c;1&#x02013;2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aesthetic changes in smile, irregular swelling of muscles, speech disorders, herniation of parotid gland, bone remodeling changes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inject within masseter boundaries; employ ultrasound guidance; monitor and adjust treatment</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Very Rare (&#x0003c;1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immune-mediated reactions</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cease treatment; consult immunologist</td></tr></tbody></table></table-wrap><table-wrap position="float" id="toxins-17-00091-t003"><object-id pub-id-type="pii">toxins-17-00091-t003_Table 3</object-id><label>Table 3</label><caption><p>Risks and mitigation methods for botulinum toxin treatment.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Risk</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mitigation Method</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Facial asymmetry</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ensure proper pre-treatment assessment and dose adjustments; inject within safety zones.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chewing weakness</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Use the lowest effective dose; avoid excessive infiltration; use ultrasound or EMG guidance.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bruising at injection site</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Apply local compression immediately post-injection; use smaller-gauge needles.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sagging skin and soft tissues</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lower injection doses; distribute treatment over several sessions; complementary injections in depressor muscles.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paradoxical swelling</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Use ultrasound guidance to confirm masseter anatomy; superficial booster doses may help if swelling persists.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diffusion to unintended muscles (e.g., risorius)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ask patients to clench their teeth during injection to identify muscle boundaries; inject well within masseter confines.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bone changes (e.g., osteopenia)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Avoid prolonged or high-dose treatments; monitor long-term effects; further research needed for validation.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unnatural facial expressions</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inject at appropriate depth and within masseter boundaries; adjust doses based on patient anatomy.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pain at injection site</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Use precise injection techniques and ensure proper patient positioning.</td></tr></tbody></table><table-wrap-foot><fn><p>Legend: This table outlines the key risks associated with botulinum toxin treatment and the corresponding mitigation methods. The risks range from mild, transient effects like bruising and pain at the injection site to more significant complications such as facial asymmetry, sagging skin, or unintended diffusion of the toxin. Mitigation strategies include precise injection techniques, ultrasound guidance, dose adjustments, and appropriate pre-treatment assessments to ensure patient safety and optimal therapeutic outcomes.</p></fn></table-wrap-foot></table-wrap></floats-group></article>